PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10751543-10 2000 These data indicate that ADP potentiates plasmin-induced platelet aggregation via the P2T(AC) receptor. Adenosine Diphosphate 25-28 purinergic receptor P2Y12 Homo sapiens 86-93 10960076-1 2000 ADP, an important agonist in thrombosis and haemostasis, has been reported to activate platelets via three receptors, P2X(1), P2Y(1) and P2T(AC). Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 137-144 10960076-9 2000 ATP stimulates P2X(1) receptors, whereas ADP is a selective agonist at metabotropic (P2Y(1) and P2T(AC)) receptors. Adenosine Diphosphate 41-44 purinergic receptor P2Y12 Homo sapiens 96-103 10446085-8 1999 Clopidogrel abolishes the inhibitory P2Y(AC) receptor-mediated ADP effects on prostaglandin E(1)-stimulated, cAMP-dependent phosphorylation of VASP without affecting epinephrine, thrombin, and thromboxane signaling. Adenosine Diphosphate 63-66 purinergic receptor P2Y12 Homo sapiens 37-44 10544922-7 1999 Adenosine-5"-phosphate-3"-phosphosulfate, a P2Y1 receptor antagonist, completely blocked ADP-induced inositol 1,4,5-trisphosphate and inositol 1,3.4-trisphosphate formation suggesting that P2TAC-mediated activation of Gi (or other G proteins) does not activate phospholipase C. These results suggest that a signaling event downstream from Gi, independent of the inhibition of platelet adenylyl cyclase, contributes to alphaIIb beta3 activation. Adenosine Diphosphate 89-92 purinergic receptor P2Y12 Homo sapiens 189-194 10506165-4 1999 ADP-induced platelet aggregation requires concomitant signaling from two P2 receptor subtypes, P2Y1 and P2T(AC), coupled to G(q) and G(i), respectively. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 104-111 10544922-2 1999 We have recently shown that concomitant intracellular signaling from both the P2TAC and P2Y1 receptors is essential for ADP-induced platelet aggregation. Adenosine Diphosphate 120-123 purinergic receptor P2Y12 Homo sapiens 78-83 34143384-0 2021 Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists. Adenosine Diphosphate 40-43 purinergic receptor P2Y12 Homo sapiens 105-110 9653141-3 1998 In this study, using specific antagonists for these two receptors, we demonstrated that concomitant intracellular signaling from both the P2TAC and P2Y1 receptors is essential for ADP-induced platelet aggregation. Adenosine Diphosphate 180-183 purinergic receptor P2Y12 Homo sapiens 138-143 16793695-3 1998 The abnormality is likely due to a severe defect of the platelet ADP receptor that is coupled to adenylate cyclase, as suggested by the following findings: 1) ADP does not normally lower cAMP levels of PGE1-treated platelets; 2) platelet shape change induced by ADP is normal; 3) the binding of [radiolabelled]ADP to formalin-fixed platelets or of the ADP analogue [radiolabelled]2-MeS-ADP to fresh platelets is severely defective. Adenosine Diphosphate 159-162 purinergic receptor P2Y12 Homo sapiens 56-77 16793695-3 1998 The abnormality is likely due to a severe defect of the platelet ADP receptor that is coupled to adenylate cyclase, as suggested by the following findings: 1) ADP does not normally lower cAMP levels of PGE1-treated platelets; 2) platelet shape change induced by ADP is normal; 3) the binding of [radiolabelled]ADP to formalin-fixed platelets or of the ADP analogue [radiolabelled]2-MeS-ADP to fresh platelets is severely defective. Adenosine Diphosphate 159-162 purinergic receptor P2Y12 Homo sapiens 56-77 16793695-3 1998 The abnormality is likely due to a severe defect of the platelet ADP receptor that is coupled to adenylate cyclase, as suggested by the following findings: 1) ADP does not normally lower cAMP levels of PGE1-treated platelets; 2) platelet shape change induced by ADP is normal; 3) the binding of [radiolabelled]ADP to formalin-fixed platelets or of the ADP analogue [radiolabelled]2-MeS-ADP to fresh platelets is severely defective. Adenosine Diphosphate 159-162 purinergic receptor P2Y12 Homo sapiens 56-77 34748820-5 2021 METHODS: We measured platelet P2Y12 expression and aggregation in response to ADP in septic patients and cecal ligation and puncture (CLP)-treated mice. Adenosine Diphosphate 78-81 purinergic receptor P2Y12 Homo sapiens 30-35 33819246-1 2021 Antagonists of the Adenosine Diphosphate (ADP) receptor, P2Y12, may inhibit platelet aggregation as a result of stimulation with arachidonic acid (AA). Adenosine Diphosphate 42-45 purinergic receptor P2Y12 Homo sapiens 57-62 34752329-2 2021 These include A1 and A2A adenosine receptors, and P2Y1 and P2Y12 receptors that respond to ADP and other nucleotides. Adenosine Diphosphate 91-94 purinergic receptor P2Y12 Homo sapiens 59-64 33652345-5 2021 RESULTS: As to preceding medicines, the proportion of patients who were functionally independent (mRS 0-2) at discharge was higher in preceding P2Y12 inhibitor that suppressed ADP- and collagen-induced macro-aggregation of platelet and Xa inhibitor or warfarin in cardioembolic stroke, but lower in P2Y12 inhibitor and Xa inhibitor or warfarin in lacunar stroke compared with no medicine. Adenosine Diphosphate 176-179 purinergic receptor P2Y12 Homo sapiens 144-149 35514261-1 2022 Platelet activation by adenosine diphosphate (ADP) is mediated through two G-protein-coupled receptors, P2Y1 and P2Y12, which signal through Gq and Gi, respectively. Adenosine Diphosphate 46-49 purinergic receptor P2Y12 Homo sapiens 113-118 35514261-10 2022 These data suggest that ADP-induced Rap1b activation requires both P2Y1 and P2Y12. Adenosine Diphosphate 24-27 purinergic receptor P2Y12 Homo sapiens 76-81 35191835-5 2022 This ADP hypersensitivity, driven by increased expression of P2Y12 and P2Y13 receptors, results in greater release of Ca2+ from the endoplasmic reticulum (ER) stores, which triggers sustained Ca2+ influx through Orai channels and alters cell motility in TREM2 KO microglia. Adenosine Diphosphate 5-8 purinergic receptor P2Y12 Homo sapiens 61-66 33309519-6 2021 The antagonism of platelet P2Y12 receptors by cangrelor, ticagrelor or active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel reduces the ADP-induced platelet aggregation in patients with thrombotic complications of vascular diseases. Adenosine Diphosphate 173-176 purinergic receptor P2Y12 Homo sapiens 27-32 33652345-5 2021 RESULTS: As to preceding medicines, the proportion of patients who were functionally independent (mRS 0-2) at discharge was higher in preceding P2Y12 inhibitor that suppressed ADP- and collagen-induced macro-aggregation of platelet and Xa inhibitor or warfarin in cardioembolic stroke, but lower in P2Y12 inhibitor and Xa inhibitor or warfarin in lacunar stroke compared with no medicine. Adenosine Diphosphate 176-179 purinergic receptor P2Y12 Homo sapiens 299-304 31649128-0 2020 Severe bleeding and absent ADP-induced platelet aggregation associated with inherited combined CalDAG-GEFI and P2Y12 deficiencies. Adenosine Diphosphate 27-30 purinergic receptor P2Y12 Homo sapiens 111-116 31949019-6 2021 The differential effect of Btk inhibition in CLEC-2 relative to GPVI signalling is explained by the positive feedback role involving Btk itself, as well as ADP and thromboxane A2 mediated activation of P2Y12 and TP receptors, respectively. Adenosine Diphosphate 156-159 purinergic receptor P2Y12 Homo sapiens 202-207 32867554-7 2020 ATP-mediated P2X7R activation and ADP-mediated activation of P2Y1R and P2Y12R play a role in pulmonary vascular tone, vascular remodeling, and inflammation in PAH. Adenosine Diphosphate 34-37 purinergic receptor P2Y12 Homo sapiens 71-77 32803122-11 2020 Conclusion ADP responsiveness is preserved under cold storage for 6 days due to stable P2Y12 activity and concomitant disintegration of inhibitory pathways enabling a higher reactivity of stored platelets. Adenosine Diphosphate 12-15 purinergic receptor P2Y12 Homo sapiens 88-93 32034708-2 2020 P2Y1 and P2Y12 both respond to ADP, but while P2Y1 links to PLC and elevates cytosolic Ca2+ concentration, P2Y12 negatively couples to adenylate cyclase, maintaining cAMP at low level. Adenosine Diphosphate 31-34 purinergic receptor P2Y12 Homo sapiens 9-14 32365642-7 2020 The function of microglia is regulated by a whole array of purinergic receptors classified as P2Y12, P2Y6, P2Y4, P2X4, P2X7, A2A, and A3, as targets of endogenous ATP, ADP, or adenosine. Adenosine Diphosphate 168-171 purinergic receptor P2Y12 Homo sapiens 94-99 32368161-1 2020 Background: High on-treatment ADP platelet reactivity (HPR) measured by VerifyNow P2Y12 assay (VN) is an established risk factor for ischemic events after percutaneous coronary intervention (PCI). Adenosine Diphosphate 30-33 purinergic receptor P2Y12 Homo sapiens 82-87 31968611-1 2020 Background: Extensive research has reported that extracellular ADP in the tumour microenvironment can stimulate platelets through interaction with the platelet receptor P2Y12. Adenosine Diphosphate 63-66 purinergic receptor P2Y12 Homo sapiens 169-174 32464678-2 2020 ADP, either derived from red blood cells or released by platelets themselves, stimulates platelets via two G protein-coupled receptors, P2Y1 and P2Y12. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 145-150 31808055-0 2020 ADP exerts P2Y12 -dependent and P2Y12 -independent effects on primary human T cell responses to stimulation. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 11-16 31808055-0 2020 ADP exerts P2Y12 -dependent and P2Y12 -independent effects on primary human T cell responses to stimulation. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 32-37 31808055-7 2020 We found that ADP affects T cell responses in term of cell activity and receptor expression through both P2Y12-dependent and P2Y12-independent pathways and other responses (cytokine secretion) primarily through P2Y12 -independent pathways. Adenosine Diphosphate 14-17 purinergic receptor P2Y12 Homo sapiens 105-110 31808055-7 2020 We found that ADP affects T cell responses in term of cell activity and receptor expression through both P2Y12-dependent and P2Y12-independent pathways and other responses (cytokine secretion) primarily through P2Y12 -independent pathways. Adenosine Diphosphate 14-17 purinergic receptor P2Y12 Homo sapiens 125-130 31808055-7 2020 We found that ADP affects T cell responses in term of cell activity and receptor expression through both P2Y12-dependent and P2Y12-independent pathways and other responses (cytokine secretion) primarily through P2Y12 -independent pathways. Adenosine Diphosphate 14-17 purinergic receptor P2Y12 Homo sapiens 125-130 32034708-4 2020 During prolonged serum deprivation, cell growth is arrested, the expression of the P2Y1 receptor strongly decreases and P2Y12 becomes a major player responsible for ADP-evoked signal transduction. Adenosine Diphosphate 165-168 purinergic receptor P2Y12 Homo sapiens 120-125 30744477-5 2020 Studies investigating the residual platelet reactivity categorized by smoking status and patients treated with platelet ADP-P2Y12 receptor inhibitors qualified the inclusion criteria. Adenosine Diphosphate 120-123 purinergic receptor P2Y12 Homo sapiens 124-129 30810440-3 2020 Thrombin activates platelets via the protease-activated receptors (PARs) 1 and 4, whereas ADP signals via the receptors P2Y1 and P2Y12 as a positive feedback mediator of platelet activation. Adenosine Diphosphate 90-93 purinergic receptor P2Y12 Homo sapiens 129-134 31376607-2 2019 Activation of P2Y12 receptors by ADP causes Gi-protein-mediated inhibition of adenylate cyclase (AC), thus limiting platelet response to anti-aggregatory effect of prostacyclin (PGI2). Adenosine Diphosphate 33-36 purinergic receptor P2Y12 Homo sapiens 14-19 31591378-0 2019 ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 104-129 31591378-12 2019 Taken together, our results indicate that P2Y12 is an important chemotaxis receptor, which triggers migration of macrophages towards nucleotide-rich, necrotic tumor areas, and modulates the inflammatory environment upon ADP binding. Adenosine Diphosphate 220-223 purinergic receptor P2Y12 Homo sapiens 42-47 31376607-3 2019 However, P2Y12 blockade reverses this ADP-induced suppression of the platelet PGI2/AC signaling pathway. Adenosine Diphosphate 38-41 purinergic receptor P2Y12 Homo sapiens 9-14 30475578-10 2019 GFA relieved mechanical and thermal hyperalgesia in the CCI rats, decreased the expression of P2Y12 mRNA and protein and phosphorylation of p38 MAPK in the DRG, and increased the ADP-downregulated cAMP concentrations in HEK293 cells transfected with P2Y12 plasmid. Adenosine Diphosphate 179-182 purinergic receptor P2Y12 Homo sapiens 250-255 31624788-1 2019 Antiplatelet therapy through inhibition of the adenosine diphosphate (ADP)/P2Y12 pathway is commonly used in the treatment of acute coronary syndrome (ACS). Adenosine Diphosphate 47-68 purinergic receptor P2Y12 Homo sapiens 75-80 31624788-1 2019 Antiplatelet therapy through inhibition of the adenosine diphosphate (ADP)/P2Y12 pathway is commonly used in the treatment of acute coronary syndrome (ACS). Adenosine Diphosphate 70-73 purinergic receptor P2Y12 Homo sapiens 75-80 29671861-2 2019 Adenosine diphosphate (ADP) receptors P2Y1 and P2Y12 both play a role in platelet activation, The present hypothesis herein is that the inhibition of these receptors may affect the release of PEVs. Adenosine Diphosphate 23-26 purinergic receptor P2Y12 Homo sapiens 47-52 30673942-8 2019 In AIS patients, 46% had suboptimal response (< 30% MAAA inhibition) to aspirin and 80% of patients on P2Y12 therapy had high platelet reactivity (> 50% ADP-induced platelet aggregation). Adenosine Diphosphate 159-162 purinergic receptor P2Y12 Homo sapiens 106-111 30302530-5 2019 Moreover, animal studies have also shown that the P2Y12 receptor may participate in atherogenesis by promoting the proliferation and migration of vascular smooth muscle cells (VSMCs) and endothelial dysfunction, and affecting inflammatory cell activities in addition to amplifying and maintaining ADP-induced platelet activation and platelet aggregation. Adenosine Diphosphate 297-300 purinergic receptor P2Y12 Homo sapiens 50-55 30734681-3 2019 Recently, the important role in the platelet aggregation of adenosine diphosphate (ADP)-activated P2Y12 and P2Y1 receptors, Gprotein coupled receptors of the P2 purinergic family, has emerged, and their inhibitors are explored as potential therapeutic antithrombotics. Adenosine Diphosphate 83-86 purinergic receptor P2Y12 Homo sapiens 98-103 29671861-7 2019 RESULTS: ADP-induced aggregation (57 +- 13 area under curve {AUC] units) was inhibited 73% by the P2Y1 antagonist, 86% by the P2Y12 antagonist, and 95% when combined (p < 0.001 for all). Adenosine Diphosphate 9-12 purinergic receptor P2Y12 Homo sapiens 126-131 30222974-3 2018 P2Y12 receptors need to be situated in these domains to be able to conduct activation signaling by adenosine diphosphate (ADP). Adenosine Diphosphate 99-120 purinergic receptor P2Y12 Homo sapiens 0-5 30445678-6 2018 P2Y12-inhibition was stronger in CANGRELOR compared to ORAL P2Y12 (adenosine diphosphate (ADP) (area under the curve (AUC)) 26.0 (5.9-71.6) vs. 160.9 (47.1-193.7)) at day 1. Adenosine Diphosphate 67-88 purinergic receptor P2Y12 Homo sapiens 0-5 30445678-6 2018 P2Y12-inhibition was stronger in CANGRELOR compared to ORAL P2Y12 (adenosine diphosphate (ADP) (area under the curve (AUC)) 26.0 (5.9-71.6) vs. 160.9 (47.1-193.7)) at day 1. Adenosine Diphosphate 67-88 purinergic receptor P2Y12 Homo sapiens 60-65 30445678-6 2018 P2Y12-inhibition was stronger in CANGRELOR compared to ORAL P2Y12 (adenosine diphosphate (ADP) (area under the curve (AUC)) 26.0 (5.9-71.6) vs. 160.9 (47.1-193.7)) at day 1. Adenosine Diphosphate 90-93 purinergic receptor P2Y12 Homo sapiens 0-5 30445678-6 2018 P2Y12-inhibition was stronger in CANGRELOR compared to ORAL P2Y12 (adenosine diphosphate (ADP) (area under the curve (AUC)) 26.0 (5.9-71.6) vs. 160.9 (47.1-193.7)) at day 1. Adenosine Diphosphate 90-93 purinergic receptor P2Y12 Homo sapiens 60-65 30222974-3 2018 P2Y12 receptors need to be situated in these domains to be able to conduct activation signaling by adenosine diphosphate (ADP). Adenosine Diphosphate 122-125 purinergic receptor P2Y12 Homo sapiens 0-5 30199785-1 2018 P2Y12 receptor antagonists are a class of drugs that act on platelet P2Y12 receptors and inhibit adenosine diphosphate-induced platelet aggregation. Adenosine Diphosphate 97-118 purinergic receptor P2Y12 Homo sapiens 0-5 30012347-8 2018 After adding the direct ADP P2Y12 inhibitor cangrelor to blood samples from all 93 patients in vitro, residual ADP-inducible platelet reactivity correlated weakly with the platelet count (r = 0.26, P = 0.01), but the platelet count did not differ significantly between patients with and without HRPR ADP (396 x 109/L [316 - 644 x 109/L] vs 340 x 109/L [241 - 489 x 109/L]; P = 0.2). Adenosine Diphosphate 111-114 purinergic receptor P2Y12 Homo sapiens 28-33 29902630-1 2018 INTRODUCTION: Adenosine diphosphate (ADP) as physiological activator of human platelets mediates its effects via three purinergic receptors: P2Y1, P2Y12 and P2X1. Adenosine Diphosphate 14-35 purinergic receptor P2Y12 Homo sapiens 147-152 29902630-1 2018 INTRODUCTION: Adenosine diphosphate (ADP) as physiological activator of human platelets mediates its effects via three purinergic receptors: P2Y1, P2Y12 and P2X1. Adenosine Diphosphate 37-40 purinergic receptor P2Y12 Homo sapiens 147-152 29456511-5 2018 Under ATP and ADP stimulation the purinergic P2Y1 receptor (R) initiates platelet activation followed by the ADP-P2Y12R-mediated amplification. Adenosine Diphosphate 14-17 purinergic receptor P2Y12 Homo sapiens 113-119 29574692-0 2018 P2Y12 receptor modulation of ADP-evoked intracellular Ca2+ signalling in THP-1 human monocytic cells. Adenosine Diphosphate 29-32 purinergic receptor P2Y12 Homo sapiens 0-5 29574692-1 2018 BACKGROUND AND PURPOSE: The Gi -coupled, ADP-activated P2Y12 receptor is well characterized as playing a key role in platelet activation via crosstalk with the P2Y1 receptor in ADP-evoked intracellular Ca2+ responses. Adenosine Diphosphate 41-44 purinergic receptor P2Y12 Homo sapiens 55-60 29574692-2 2018 However, there is limited knowledge on the role of P2Y12 receptors in ADP-evoked Ca2+ responses in other blood cells. Adenosine Diphosphate 70-73 purinergic receptor P2Y12 Homo sapiens 51-56 29574692-3 2018 Here, we investigated the role of P2Y12 receptor activation in the modulation of ADP-evoked Ca2+ responses in human THP-1 monocytic cells. Adenosine Diphosphate 81-84 purinergic receptor P2Y12 Homo sapiens 34-39 29574692-7 2018 ADP-evoked responses were attenuated either with pertussis toxin treatment, or P2Y12 receptor inhibition with two chemically distinct antagonists (ticagrelor, IC50 5.3 muM; PSB-0739, IC50 5.6 muM). Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 79-84 29574692-8 2018 ADP-evoked responses were suppressed following siRNA-mediated P2Y12 gene knockdown. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 62-67 28523947-1 2018 The release of ADP from platelet dense granules and its binding to platelet P2Y12 receptors is key to amplifying the initial hemostatic response and propagating thrombus formation. Adenosine Diphosphate 15-18 purinergic receptor P2Y12 Homo sapiens 76-81 28523947-6 2018 These results suggest that inhibition of P2Y12 with MRS2395 may act in concert with PAR-1 signaling and result in the aberrant release of ADP by platelet dense granules, thus reducing or counteracting the anticipated anti-platelet efficacy of this inhibitor. Adenosine Diphosphate 138-141 purinergic receptor P2Y12 Homo sapiens 41-46 29350995-1 2018 P2Y12 belongs to a group of G protein-coupled (GPCR) purinergic receptors and is a receptor for adenosine diphosphate (ADP). Adenosine Diphosphate 96-117 purinergic receptor P2Y12 Homo sapiens 0-5 29350995-1 2018 P2Y12 belongs to a group of G protein-coupled (GPCR) purinergic receptors and is a receptor for adenosine diphosphate (ADP). Adenosine Diphosphate 119-122 purinergic receptor P2Y12 Homo sapiens 0-5 29968812-9 2018 P2Y12 and TPalpha, receptors for ADP and thromboxane A2, respectively, have been reported to be in platelet lipid rafts. Adenosine Diphosphate 33-36 purinergic receptor P2Y12 Homo sapiens 0-5 29575062-0 2018 Restored response to ADP downstream of purinergic P2Y12 receptor in apheresis platelets after pathogen-reducing xenon flash treatment. Adenosine Diphosphate 21-24 purinergic receptor P2Y12 Homo sapiens 50-55 29468430-10 2018 P2Y12 inhibition was recorded by stimulation of platelet aggregation with adenosine diphosphate. Adenosine Diphosphate 74-95 purinergic receptor P2Y12 Homo sapiens 0-5 29439388-2 2018 Platelet activation by ADP is associated with the G protein-coupled receptors P2Y1 and P2Y12. Adenosine Diphosphate 23-26 purinergic receptor P2Y12 Homo sapiens 87-92 29322294-2 2018 Platelet activation is largely mediated through ADP engagement of purinergic P2Y12 receptors on platelets. Adenosine Diphosphate 48-51 purinergic receptor P2Y12 Homo sapiens 77-82 30346865-6 2018 P2Y12 inhibiting medications had increased ADP inhibition (p = 0.0077). Adenosine Diphosphate 43-46 purinergic receptor P2Y12 Homo sapiens 0-5 28921624-3 2018 METHODS: This was a single-centre, prospective, randomized clinical trial involving 60 hospitalized Adenosine Diphosphate (ADP) P2Y12 receptor inhibitor-naive patients with chronic kidney disease (CKD) (estimated glomerular filtration rate <60 ml min-1 1.73 m-2 ) and non-ST-elevation acute coronary syndromes (NSTE-ACS). Adenosine Diphosphate 100-121 purinergic receptor P2Y12 Homo sapiens 128-133 28921624-3 2018 METHODS: This was a single-centre, prospective, randomized clinical trial involving 60 hospitalized Adenosine Diphosphate (ADP) P2Y12 receptor inhibitor-naive patients with chronic kidney disease (CKD) (estimated glomerular filtration rate <60 ml min-1 1.73 m-2 ) and non-ST-elevation acute coronary syndromes (NSTE-ACS). Adenosine Diphosphate 123-126 purinergic receptor P2Y12 Homo sapiens 128-133 28511553-9 2018 The ADP test results were also significantly lower in patients treated with a P2Y12 inhibitor (control: 77.7 [21.7] U, P2Y12 inhibitor: 37.3 [20.4] U, P < .01). Adenosine Diphosphate 4-7 purinergic receptor P2Y12 Homo sapiens 78-83 29171876-1 2018 BACKGROUND: Anaemic patients undergoing angioplasty and stenting are at an increased risk of ischaemic events, which may be caused by an inadequate response to antiplatelet therapy with adenosine diphosphate (ADP) P2Y12 inhibitors. Adenosine Diphosphate 209-212 purinergic receptor P2Y12 Homo sapiens 214-219 29171876-7 2018 Moreover, by LTA maximal aggregation in response to ADP was significantly higher in patients with anaemia in both groups (both P < .05), and anaemic patients in group 1 had a significantly higher on-treatment platelet reactivity by the VerifyNow P2Y12 assay and the Impact-R than those without anaemia (both P < .001). Adenosine Diphosphate 52-55 purinergic receptor P2Y12 Homo sapiens 249-254 29188558-2 2018 We illustrate here how this applies to A2A adenosine receptors (ARs) and to P2Y1 and P2Y12 receptors (P2YRs) for ADP. Adenosine Diphosphate 113-116 purinergic receptor P2Y12 Homo sapiens 85-90 28511553-9 2018 The ADP test results were also significantly lower in patients treated with a P2Y12 inhibitor (control: 77.7 [21.7] U, P2Y12 inhibitor: 37.3 [20.4] U, P < .01). Adenosine Diphosphate 4-7 purinergic receptor P2Y12 Homo sapiens 119-124 29296928-3 2017 In contrast, adenosine 5"-diphosphate (ADP)/P2Y12 signaling contributes to the accumulation of partially activated, loosely packed platelets in a shell overlying the core. Adenosine Diphosphate 13-37 purinergic receptor P2Y12 Homo sapiens 44-49 29296928-3 2017 In contrast, adenosine 5"-diphosphate (ADP)/P2Y12 signaling contributes to the accumulation of partially activated, loosely packed platelets in a shell overlying the core. Adenosine Diphosphate 39-42 purinergic receptor P2Y12 Homo sapiens 44-49 28753204-5 2017 Mechanistically, ASK1-JNK/p38 axis phosphorylates an ADP receptor P2Y12 at Thr345, which is required for the ADP-dependent sustained Akt activity that is vital to normal platelet functions. Adenosine Diphosphate 53-56 purinergic receptor P2Y12 Homo sapiens 66-71 28928091-2 2017 To this end, adenosine diphosphate (ADP) is an important platelet activator that acts by binding to the G-protein coupled P2Y1 and P2Y12 receptors. Adenosine Diphosphate 13-34 purinergic receptor P2Y12 Homo sapiens 131-136 28928091-2 2017 To this end, adenosine diphosphate (ADP) is an important platelet activator that acts by binding to the G-protein coupled P2Y1 and P2Y12 receptors. Adenosine Diphosphate 36-39 purinergic receptor P2Y12 Homo sapiens 131-136 28928091-5 2017 Our in vitro studies revealed that the P2Y12Ab could effectively inhibit aggregation induced by ADP, as well as that triggered by the thromboxane receptor agonist U46619. Adenosine Diphosphate 96-99 purinergic receptor P2Y12 Homo sapiens 39-44 27848264-2 2017 We hypothesized that red cell adenosine diphosphate (ADP) release results in significant platelet activation in hemolysis and that this prothrombotic state can be prevented by inhibition of the ADP P2Y12 receptor. Adenosine Diphosphate 30-51 purinergic receptor P2Y12 Homo sapiens 198-203 27848264-2 2017 We hypothesized that red cell adenosine diphosphate (ADP) release results in significant platelet activation in hemolysis and that this prothrombotic state can be prevented by inhibition of the ADP P2Y12 receptor. Adenosine Diphosphate 53-56 purinergic receptor P2Y12 Homo sapiens 198-203 27885904-11 2017 A proportion of P2Y12-inhibitor responsive patients according to VerifyNow, displayed normal fibrinogen binding assessed with flow cytometry after stimulation with PAR-agonists or CRP despite full inhibition of the response to ADP, indicating suboptimal platelet inhibition. Adenosine Diphosphate 227-230 purinergic receptor P2Y12 Homo sapiens 16-21 27628007-2 2017 P2Y12 receptor is physiologically activated by ADP and inhibits adenyl cyclase (AC) to decrease cyclic AMP (cAMP) level, resulting in platelet aggregation. Adenosine Diphosphate 47-50 purinergic receptor P2Y12 Homo sapiens 0-5 28637879-9 2017 P2Y12 expression correlates with ADP-induced platelet aggregation (r=0.89, P<0.01). Adenosine Diphosphate 33-36 purinergic receptor P2Y12 Homo sapiens 0-5 28800362-0 2017 Nucleotide transmitters ATP and ADP mediate intercellular calcium wave communication via P2Y12/13 receptors among BV-2 microglia. Adenosine Diphosphate 32-35 purinergic receptor P2Y12 Homo sapiens 89-94 28800362-11 2017 Taken together, these results demonstrated that the nucleotides ATP and ADP were predominant signal transmitters in mechanical stimulation-induced ICW communication through acting on P2Y12/13 receptors in BV-2 microglia. Adenosine Diphosphate 72-75 purinergic receptor P2Y12 Homo sapiens 183-188 28562105-3 2017 Areas covered: The oral thienopyridine, prasugrel hydrochloride, irreversibly inhibits the P2Y12 receptors, inhibiting ADP-dependent platelet activation. Adenosine Diphosphate 119-122 purinergic receptor P2Y12 Homo sapiens 91-96 28255814-2 2017 Adenosine diphosphate (ADP) activated P2Y12 receptor also plays a key role in platelet activation and aggregation. Adenosine Diphosphate 0-21 purinergic receptor P2Y12 Homo sapiens 38-43 28255814-2 2017 Adenosine diphosphate (ADP) activated P2Y12 receptor also plays a key role in platelet activation and aggregation. Adenosine Diphosphate 23-26 purinergic receptor P2Y12 Homo sapiens 38-43 28144998-4 2017 ADP acting on P2Y12 receptors induce process extension of microglia thereby attracting microglia to the site of adenosine tri-phosphate/ADP leaking or release. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 14-19 28144998-4 2017 ADP acting on P2Y12 receptors induce process extension of microglia thereby attracting microglia to the site of adenosine tri-phosphate/ADP leaking or release. Adenosine Diphosphate 136-139 purinergic receptor P2Y12 Homo sapiens 14-19 28144998-10 2017 These data indicate that microglial P2Y12 receptors are utilized to trigger an acute inflammatory response in microglia via rapid CCL3 induction after ADP stimulation. Adenosine Diphosphate 151-154 purinergic receptor P2Y12 Homo sapiens 36-41 28383427-2 2017 Clopidogrel targets the platelet membrane receptor P2RY12 to inhibit platelet aggregation via adenosine diphosphate (ADP). Adenosine Diphosphate 94-115 purinergic receptor P2Y12 Homo sapiens 51-57 28383427-2 2017 Clopidogrel targets the platelet membrane receptor P2RY12 to inhibit platelet aggregation via adenosine diphosphate (ADP). Adenosine Diphosphate 117-120 purinergic receptor P2Y12 Homo sapiens 51-57 27480079-5 2016 Adenosine diphosphate (ADP) was used to stimulate the P2Y1/P2Y12 pathway of platelet activation to mimic the in vivo thrombogenic pathway. Adenosine Diphosphate 0-21 purinergic receptor P2Y12 Homo sapiens 59-64 27605392-1 2016 Ticagrelor is an antagonist of the platelet P2Y12 receptor for ADP, approved for the prevention of thromboembolic events in patients with acute coronary syndrome. Adenosine Diphosphate 63-66 purinergic receptor P2Y12 Homo sapiens 44-49 26516174-0 2016 Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2. Adenosine Diphosphate 46-67 purinergic receptor P2Y12 Homo sapiens 27-41 26516174-1 2016 AIMS: Patients with acute coronary syndromes (ACSs) are treated with acetylsalicylic acid (ASA) and antagonists of the P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP). Adenosine Diphosphate 147-168 purinergic receptor P2Y12 Homo sapiens 119-133 26516174-1 2016 AIMS: Patients with acute coronary syndromes (ACSs) are treated with acetylsalicylic acid (ASA) and antagonists of the P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP). Adenosine Diphosphate 147-168 purinergic receptor P2Y12 Homo sapiens 135-141 26516174-1 2016 AIMS: Patients with acute coronary syndromes (ACSs) are treated with acetylsalicylic acid (ASA) and antagonists of the P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP). Adenosine Diphosphate 170-173 purinergic receptor P2Y12 Homo sapiens 119-133 26516174-1 2016 AIMS: Patients with acute coronary syndromes (ACSs) are treated with acetylsalicylic acid (ASA) and antagonists of the P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP). Adenosine Diphosphate 170-173 purinergic receptor P2Y12 Homo sapiens 135-141 27172914-6 2016 ADP inhibited currents through Cav2.2 channels via both P2Y1 and P2Y12 receptors with phospholipase C and pertussis toxin-sensitive G proteins being involved, respectively. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 65-70 27740874-3 2016 Ticagrelor is a reversibly binding oral P2Y12 receptor blocker that mediates potent inhibition of adenosine diphosphate-induced platelet function. Adenosine Diphosphate 98-119 purinergic receptor P2Y12 Homo sapiens 40-45 27480079-5 2016 Adenosine diphosphate (ADP) was used to stimulate the P2Y1/P2Y12 pathway of platelet activation to mimic the in vivo thrombogenic pathway. Adenosine Diphosphate 23-26 purinergic receptor P2Y12 Homo sapiens 59-64 27480079-6 2016 Platelet aggregation studies utilised both ADP and collagen as exogenous platelet agonists to target both P2Y1/P2Y12 and GPVI pathways of thrombus formation. Adenosine Diphosphate 43-46 purinergic receptor P2Y12 Homo sapiens 111-116 26562035-6 2016 RESULTS: Consensus guidelines suggest that a platelet aggregation response in response to the agonist ADP of <57% is an adequate therapeutic response to P2Y12 inhibition. Adenosine Diphosphate 102-105 purinergic receptor P2Y12 Homo sapiens 156-161 26837379-7 2016 Relative ADP induced aggregation (r-ADP-agg) was defined as the ADP-TRAP-ratio to reflect an individual degree of P2Y12-dependent platelet inhibition. Adenosine Diphosphate 9-12 purinergic receptor P2Y12 Homo sapiens 114-119 26808867-3 2016 OBJECTIVES: Since ADP mediates its effects via three purinergic receptors P2Y1, P2X1 and P2Y12, their surface expression and function were investigated in washed platelets and, for comparison, in platelet-rich-plasma (PRP) at different time points for up to 2 hours after preparation. Adenosine Diphosphate 18-21 purinergic receptor P2Y12 Homo sapiens 89-94 26519900-4 2016 One important example is the ADP-induced platelet aggregation mediated by P2Y1 and P2Y12 receptors. Adenosine Diphosphate 29-32 purinergic receptor P2Y12 Homo sapiens 83-88 26885820-0 2016 The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count. Adenosine Diphosphate 13-16 purinergic receptor P2Y12 Homo sapiens 66-71 26885820-1 2016 OBJECTIVE: This study aimed to assess the association of clinical factors with P2Y12-dependent platelet inhibition as monitored by the ratio of ADP- to TRAP-induced platelet aggregation and conventional ADP-induced aggregation, respectively. Adenosine Diphosphate 144-147 purinergic receptor P2Y12 Homo sapiens 79-84 26885820-1 2016 OBJECTIVE: This study aimed to assess the association of clinical factors with P2Y12-dependent platelet inhibition as monitored by the ratio of ADP- to TRAP-induced platelet aggregation and conventional ADP-induced aggregation, respectively. Adenosine Diphosphate 203-206 purinergic receptor P2Y12 Homo sapiens 79-84 26885820-5 2016 Relative ADP-induced aggregation (r-ADP-agg) was defined as the ratio of ADP- to TRAP- induced aggregation reflecting the individual degree of P2Y12-mediated platelet reactivity. Adenosine Diphosphate 9-12 purinergic receptor P2Y12 Homo sapiens 143-148 26885820-11 2016 CONCLUSION: The ratio of ADP- to TRAP-induced platelet aggregation quantifies P2Y12-dependent platelet inhibition independently of the platelet count in contrast to conventional ADP-induced aggregation. Adenosine Diphosphate 25-28 purinergic receptor P2Y12 Homo sapiens 78-83 26885820-13 2016 Thus, the r-ADP-agg is a more valid reflecting platelet aggregation and potentially prognosis after coronary stent-implantation in P2Y12-mediated HPR than conventional ADP-induced platelet aggregation. Adenosine Diphosphate 12-15 purinergic receptor P2Y12 Homo sapiens 131-136 26391841-0 2015 Modulation and pre-amplification of PAR1 signaling by ADP acting via the P2Y12 receptor during platelet subpopulation formation. Adenosine Diphosphate 54-57 purinergic receptor P2Y12 Homo sapiens 73-78 27028818-8 2016 According to the data obtained by Western blot, upon the cell activation with ADP, the number of GP IIb-IIIa and P2Y12 receptors increases, which may serve as evidence of these proteins being synthesized in the activated platelets. Adenosine Diphosphate 78-81 purinergic receptor P2Y12 Homo sapiens 113-118 25970449-6 2016 Notably, lysosomal exocytosis in response to thrombin was significantly reduced if the secondary activation by ADP was inhibited by the P2Y12 antagonist cangrelor, while inhibition of thromboxane A2 formation by treatment with acetylsalicylic acid was of minor importance in this regard. Adenosine Diphosphate 111-114 purinergic receptor P2Y12 Homo sapiens 136-141 25970449-9 2016 Furthermore, we suggest that secondary release of ADP and concomitant signaling via PAR1/4- and P2Y12 receptors is important for efficient platelet lysosomal exocytosis by thrombin. Adenosine Diphosphate 50-53 purinergic receptor P2Y12 Homo sapiens 96-101 26391841-4 2015 However, ADP acting through the P2Y12 receptor was shown to increase the PS-exposing (PS+) platelets fraction produced by thrombin or thrombin-plus-collagen via an unknown mechanism. Adenosine Diphosphate 9-12 purinergic receptor P2Y12 Homo sapiens 32-37 26391841-8 2015 ADP stimulation of P2Y12 led to cAMP decrease that, in turn, caused changes in phospholipase C phosphorylation by protein kinase A, increase in cytoplasmic calcium level and, consequently, PS+ platelet formation. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 19-24 26448282-4 2015 We found that adenosine 5"-diphosphate (ADP) induced human eosinophils to secrete eosinophil peroxidase (EPO) in a P2Y12R dependent manner. Adenosine Diphosphate 14-38 purinergic receptor P2Y12 Homo sapiens 115-121 26448282-4 2015 We found that adenosine 5"-diphosphate (ADP) induced human eosinophils to secrete eosinophil peroxidase (EPO) in a P2Y12R dependent manner. Adenosine Diphosphate 40-43 purinergic receptor P2Y12 Homo sapiens 115-121 26297398-6 2015 RESULTS: In control blood samples, P2Y12, TPalpha or PAR1 antagonists markedly reduced ADP-test, ASPI-test and TRAP-test results respectively. Adenosine Diphosphate 87-90 purinergic receptor P2Y12 Homo sapiens 35-40 25645301-11 2015 We suggest that the prothrombotic nature of smoking could be a cause of elevated ADP, and this may explain why cardiovascular patients who smoke benefit from platelet P2Y12 receptor antagonists more than their nonsmoking peers. Adenosine Diphosphate 81-84 purinergic receptor P2Y12 Homo sapiens 167-172 25882759-1 2015 INTRODUCTION: ADP-induced platelet activation via P2Y12 receptor plays a pivotal role in the pathophysiology of arterial thrombosis and acute coronary syndrome. Adenosine Diphosphate 14-17 purinergic receptor P2Y12 Homo sapiens 50-55 26149010-3 2015 Defects of P2Y12R should be suspected when ADP, even at high concentrations (>= 10 mum), is unable to induce full, irreversible platelet aggregation. Adenosine Diphosphate 43-46 purinergic receptor P2Y12 Homo sapiens 11-17 25641006-5 2015 RESULTS: Our results demonstrate that clopidogrel had no and prasugrel had only mild effects on donor PLT function, but the reversible P2Y12 inhibitor ticagrelor completely abolished adenosine diphosphate-mediated PLT activation in all assays tested. Adenosine Diphosphate 183-204 purinergic receptor P2Y12 Homo sapiens 135-140 25428217-1 2015 Defects of the platelet P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP) are associated with increased bleeding risk. Adenosine Diphosphate 52-73 purinergic receptor P2Y12 Homo sapiens 24-38 25428217-1 2015 Defects of the platelet P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP) are associated with increased bleeding risk. Adenosine Diphosphate 52-73 purinergic receptor P2Y12 Homo sapiens 40-46 25428217-1 2015 Defects of the platelet P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP) are associated with increased bleeding risk. Adenosine Diphosphate 75-78 purinergic receptor P2Y12 Homo sapiens 24-38 25428217-1 2015 Defects of the platelet P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP) are associated with increased bleeding risk. Adenosine Diphosphate 75-78 purinergic receptor P2Y12 Homo sapiens 40-46 25428217-10 2015 These studies delineate a region of P2Y12R required for normal function after ADP binding. Adenosine Diphosphate 78-81 purinergic receptor P2Y12 Homo sapiens 36-42 25837834-2 2015 The human P2YRs are fully activated by ATP (P2Y2 and P2Y11), ADP (P2Y1, P2Y12, and P2Y13), UTP (P2Y2 and P2Y4), UDP (P2Y6 and P2Y14), and UDP glucose (P2Y14). Adenosine Diphosphate 61-64 purinergic receptor P2Y12 Homo sapiens 72-77 25976494-2 2015 Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12 inhibitors clopidogrel, prasugrel and ticagrelor. Adenosine Diphosphate 107-110 purinergic receptor P2Y12 Homo sapiens 121-126 25821842-4 2015 In response to ADP, the endogenous ligand of P2Y12, M2 microglia have increased ligand-mediated calcium responses, which are blocked by selective P2Y12 antagonism. Adenosine Diphosphate 15-18 purinergic receptor P2Y12 Homo sapiens 45-50 25821842-4 2015 In response to ADP, the endogenous ligand of P2Y12, M2 microglia have increased ligand-mediated calcium responses, which are blocked by selective P2Y12 antagonism. Adenosine Diphosphate 15-18 purinergic receptor P2Y12 Homo sapiens 146-151 25297118-6 2015 P2RY12 (purinergic receptor P2Y, G-protein coupled, 12) gene is coding a receptor, which is situated on the surface of the platelets and plays a role in ADP-induced platelet aggregation. Adenosine Diphosphate 153-156 purinergic receptor P2Y12 Homo sapiens 0-6 25297118-6 2015 P2RY12 (purinergic receptor P2Y, G-protein coupled, 12) gene is coding a receptor, which is situated on the surface of the platelets and plays a role in ADP-induced platelet aggregation. Adenosine Diphosphate 153-156 purinergic receptor P2Y12 Homo sapiens 8-54 25350775-8 2015 ADP-induced platelet reactivity was decreased in the patients treated with prasugrel or ticagrelor compared with those on clopidogrel (mean +- SD: 139 +- 71 vs. 313 +- 162 arbitrary units [AU]*min, p = 0.006), due to a more potent antiplatelet activity of the novel P2Y12 antagonists. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 266-271 25350775-9 2015 Consequently, six out of seven patients in the lower tertile of the ADP-induced platelet aggregation were treated with the newer P2Y12 blockers, whereas six out of seven patients in the upper tertile were on clopidogrel. Adenosine Diphosphate 68-71 purinergic receptor P2Y12 Homo sapiens 129-134 25734957-0 2015 Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography. Adenosine Diphosphate 62-65 purinergic receptor P2Y12 Homo sapiens 44-49 25734957-7 2015 In conclusion, PGE1 potentiates the anti-aggregatory effects of P2Y12 blockade on ADP-mediated platelet aggregation. Adenosine Diphosphate 82-85 purinergic receptor P2Y12 Homo sapiens 64-69 25115434-5 2014 Significant correlations were found between the area under the time-concentration curve (AUC0- ) of CAMD and both the absolute ADP-induced P2Y12 receptor-activated platelet aggregation (r = -0.60, P = 0.0007) and the percentage inhibition of aggregation (r = 0.59, P = 0.0009). Adenosine Diphosphate 128-131 purinergic receptor P2Y12 Homo sapiens 140-145 26632148-6 2015 ADP activates human platelets by stimulating both P2Y1R and P2Y12R, which act sequentially and in concert to achieve complete platelet aggregation. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 60-66 25297833-7 2014 Evidence available from studies evaluating aspirin resistance and high and low on-treatment platelet reactivity to ADP during P2Y12 receptor blocker therapy was collected from a selective literature search. Adenosine Diphosphate 115-118 purinergic receptor P2Y12 Homo sapiens 126-131 25427105-10 2014 Adjusting for the influence of hematocrit improved the strength of the correlation between the VerifyNow P2Y12 and MEA ADP assay results. Adenosine Diphosphate 119-122 purinergic receptor P2Y12 Homo sapiens 105-110 25115434-7 2014 Neither the absolute ADP-induced P2Y12 receptor-activated platelet aggregation, exposure to CAMD nor the pharmacokinetic parameters of proguanil, cycloguanil and 4-CPB exhibited any significant differences among the genotype groups. Adenosine Diphosphate 21-24 purinergic receptor P2Y12 Homo sapiens 33-38 25075638-3 2014 It is a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists described in the literature. Adenosine Diphosphate 115-118 purinergic receptor P2Y12 Homo sapiens 49-54 25502126-2 2014 BACKGROUND: VN-P2Y12 is a point-of-care device that measures platelet reactivity to adenosine diphosphate. Adenosine Diphosphate 84-105 purinergic receptor P2Y12 Homo sapiens 15-20 25037531-2 2014 Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12 inhibitors clopidogrel, prasugrel and ticagrelor. Adenosine Diphosphate 107-110 purinergic receptor P2Y12 Homo sapiens 121-126 25186974-6 2014 RESULTS: The natural agonist ADP inhibited forskolin-induced cAMP formation at the wild-type P2Y12 -receptor with a lower potency (EC50 209 nm) than the synthetic agonist 2-methylthio-ADP (EC50 1.0 nm). Adenosine Diphosphate 29-32 purinergic receptor P2Y12 Homo sapiens 93-98 25186974-10 2014 In cells expressing a recombinant C194A(5.43) -mutant P2Y12 -receptor construct, ticagrelor lost antagonistic potency when tested against ADP or 2-methylthio-ADP. Adenosine Diphosphate 138-141 purinergic receptor P2Y12 Homo sapiens 54-59 25186974-11 2014 CONCLUSIONS: The experiments reveal a surmountable and competitive mode of antagonism of ticagrelor at P2Y12 -receptors activated by either the natural agonist ADP or the synthetic agonist 2-methylthio-ADP. Adenosine Diphosphate 160-163 purinergic receptor P2Y12 Homo sapiens 103-108 25075638-3 2014 It is a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists described in the literature. Adenosine Diphosphate 115-118 purinergic receptor P2Y12 Homo sapiens 158-163 24705415-9 2014 Synergistic signaling via P2Y12 and thromboxane receptor through secreted ADP and TxA2, respectively, were important for echicetin bead triggered platelet activation. Adenosine Diphosphate 74-77 purinergic receptor P2Y12 Homo sapiens 26-31 25100739-3 2014 To devise a different strategy, we engineered and optimized the apyrase activity of human nucleoside triphosphate diphosphohydrolase-3 (CD39L3) to enhance scavenging of extracellular adenosine diphosphate, a predominant ligand of P2Y12 receptors. Adenosine Diphosphate 183-204 purinergic receptor P2Y12 Homo sapiens 230-235 24816772-8 2014 Moreover, our data indicates that ApoBDS-1-induced platelet activation is partially dependent of positive feedback from ADP on P2Y1 and P2Y12, and TxA2. Adenosine Diphosphate 120-123 purinergic receptor P2Y12 Homo sapiens 136-141 24671606-9 2014 In conclusion, VN-P2Y12 overestimates the functional effects of clopidogrel in some individuals, possibly because it utilises PGE1 in addition to ADP. Adenosine Diphosphate 146-149 purinergic receptor P2Y12 Homo sapiens 18-23 25163307-4 2014 New generation of P2Y12 ADP antagonists including prasugrel and ticagrelor are available, but only in patients with acute coronary syndrome. Adenosine Diphosphate 24-27 purinergic receptor P2Y12 Homo sapiens 18-23 24258486-6 2014 The change in VASP-P brought about by adding ADP to PGE1-stimulated platelets is a combination of the effect of ADP at the P2Y12 receptor and of PGE1 at both IP and EP3 receptors. Adenosine Diphosphate 45-48 purinergic receptor P2Y12 Homo sapiens 123-128 24258486-6 2014 The change in VASP-P brought about by adding ADP to PGE1-stimulated platelets is a combination of the effect of ADP at the P2Y12 receptor and of PGE1 at both IP and EP3 receptors. Adenosine Diphosphate 112-115 purinergic receptor P2Y12 Homo sapiens 123-128 25247182-2 2014 Adenosine diphosphate (ADP) activates gpiibiiia and P2Y12, causing platelet aggregation and thrombus stabilization during blood loss. Adenosine Diphosphate 0-21 purinergic receptor P2Y12 Homo sapiens 52-57 24331208-0 2014 Usefulness of the INNOVANCE PFA P2Y test cartridge for the detection of patients with congenital defects of the platelet P2Y12 receptor for adenosine diphosphate. Adenosine Diphosphate 140-161 purinergic receptor P2Y12 Homo sapiens 121-126 25247182-2 2014 Adenosine diphosphate (ADP) activates gpiibiiia and P2Y12, causing platelet aggregation and thrombus stabilization during blood loss. Adenosine Diphosphate 23-26 purinergic receptor P2Y12 Homo sapiens 52-57 24272707-2 2014 In addition to the accepted roles for the P2 X4,7 and P2 Y12 receptors activated by adenosine triphosphate (ATP) and adenosine diphosphate, respectively, recent evidence suggests a role for the adenosine A2A receptor in microglial cytoskeletal rearrangements. Adenosine Diphosphate 117-138 purinergic receptor P2Y12 Homo sapiens 42-60 24845219-2 2014 The P2Y12 receptor is a Gi-coupled receptor that not only regulates ADP-induced aggregation but can also dramatically potentiate secretion, when platelets are activated by other stimuli. Adenosine Diphosphate 68-71 purinergic receptor P2Y12 Homo sapiens 4-9 23885646-1 2014 Clopidogrel is a thienopyridine that selectively and irreversibly inhibits the ADP purinergic receptor P2Y12 and the subsequent ADP-mediated platelet activation. Adenosine Diphosphate 79-82 purinergic receptor P2Y12 Homo sapiens 103-108 23917456-3 2013 Platelet P2Y12 receptor activation by adenosine diphosphate facilitates non-ADP agonist-mediated platelet aggregation, dense granule secretion, procoagulant activity, and the phosphorylation of several intraplatelet proteins, making it an ideal drug target. Adenosine Diphosphate 38-59 purinergic receptor P2Y12 Homo sapiens 9-14 24118870-1 2013 BACKGROUND: The VerifyNow P2Y12 assay assesses the adequacy of clopidogrel therapy by measuring ADP-induced platelet activation in whole blood. Adenosine Diphosphate 96-99 purinergic receptor P2Y12 Homo sapiens 26-31 24118870-4 2013 PATIENTS/METHODS: Adenosine diphosphate-induced platelet activation was measured using the VerifyNow P2Y12 assay, whole blood impedance and light transmission platelet aggregometry (LTA) before and after clopidogrel loading in 113 patients undergoing elective cardiac catheterization. Adenosine Diphosphate 18-39 purinergic receptor P2Y12 Homo sapiens 101-106 23884248-2 2013 Different aspirin dosing regimens have been suggested to impact outcomes when used in combination with adenosine diphosphate (ADP) P2Y12 receptor antagonists. Adenosine Diphosphate 103-124 purinergic receptor P2Y12 Homo sapiens 131-136 23884248-2 2013 Different aspirin dosing regimens have been suggested to impact outcomes when used in combination with adenosine diphosphate (ADP) P2Y12 receptor antagonists. Adenosine Diphosphate 126-129 purinergic receptor P2Y12 Homo sapiens 131-136 24003163-5 2013 Particularly significant among these secondary mediators is ADP, which, acting through platelet P2Y12 receptors, strongly amplifies aggregation. Adenosine Diphosphate 60-63 purinergic receptor P2Y12 Homo sapiens 96-101 24071464-1 2013 BACKGROUND: Platelets express two ADP receptors namely P2Y1 and P2Y12 that regulate ADP and other agonists-induced platelet aggregation. Adenosine Diphosphate 34-37 purinergic receptor P2Y12 Homo sapiens 64-69 23849096-0 2013 Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population. Adenosine Diphosphate 54-57 purinergic receptor P2Y12 Homo sapiens 19-24 23849096-1 2013 BACKGROUND: P2Y1 and P2Y12 receptors are expressed in platelet membranes and are involved in ADP-induced platelet aggregation. Adenosine Diphosphate 93-96 purinergic receptor P2Y12 Homo sapiens 21-26 23849096-2 2013 Genetic polymorphisms of P2Y1 and P2Y12 play a major role in the variation of ADP-induced platelet aggregation and in response in antiplatelet therapy. Adenosine Diphosphate 78-81 purinergic receptor P2Y12 Homo sapiens 34-39 23849096-7 2013 However, the P2Y12 c.52G>T polymorphism caused a substantial difference in ADP-induced maximal platelet aggregation (62.75% for c.52GG, 66.27% for c.52GT, and 80.60% for c.52TT; P=0.0092). Adenosine Diphosphate 78-81 purinergic receptor P2Y12 Homo sapiens 13-18 23859572-2 2013 PATIENTS & METHODS: The inhibition of adenosine diphosphate-induced platelet aggregation was measured pre- and post-administration using the VerifyNow( ) P2Y12 assay. Adenosine Diphosphate 42-63 purinergic receptor P2Y12 Homo sapiens 158-163 23623170-6 2013 HRPR in response to adenosine diphosphate was seen in 150 (48.1%), 48 (15.3%), 106 (33.7%), and 118 (38.3%) patients by the VASP assay, LTA, the VerifyNow P2Y12 assay, and MEA, respectively. Adenosine Diphosphate 20-41 purinergic receptor P2Y12 Homo sapiens 155-160 23612493-2 2013 P2Y12 receptor is the major platelet receptor that mediates ADP-induced aggregation, P2Y12 receptor inhibitors such as clopidogrel and prasugrel inhibit platelet aggregation, and thus, they are used in the treatment and prevention of coronary artery disease. Adenosine Diphosphate 60-63 purinergic receptor P2Y12 Homo sapiens 0-5 23612493-2 2013 P2Y12 receptor is the major platelet receptor that mediates ADP-induced aggregation, P2Y12 receptor inhibitors such as clopidogrel and prasugrel inhibit platelet aggregation, and thus, they are used in the treatment and prevention of coronary artery disease. Adenosine Diphosphate 60-63 purinergic receptor P2Y12 Homo sapiens 85-90 23435863-2 2013 Current anti-platelet treatments are mainly based on inhibition of two important pathways of platelet activation: thromboxane A2 (TXA2) mediated (aspirin) and adenosine diphosphate (ADP)-P2Y12 receptor mediated (clopidogrel, prasugrel, and ticagrelor). Adenosine Diphosphate 159-180 purinergic receptor P2Y12 Homo sapiens 187-192 23171128-1 2013 AIMS: Prasugrel is a novel thienopyridine P2Y12 adenosine diphosphate (ADP) receptor antagonist that inhibits ADP-mediated platelet activation and aggregation. Adenosine Diphosphate 71-74 purinergic receptor P2Y12 Homo sapiens 42-47 23652405-4 2013 RESULTS: Our data show time-dependent platelet activation by GPVI agonist (collagen related peptide; CRP), PAR-1 agonist (SFLLRN), P2Y12 agonist (ADP), and thromboxane receptor agonist (U46619) in a platelet concentrate. Adenosine Diphosphate 146-149 purinergic receptor P2Y12 Homo sapiens 131-136 23387322-1 2013 P2Y12 receptor internalization and recycling play an essential role in ADP-induced platelet activation. Adenosine Diphosphate 71-74 purinergic receptor P2Y12 Homo sapiens 0-5 23387322-4 2013 Treatment with ADP resulted in delayed Rab5-dependent internalization of P341A when compared with WT P2Y12 . Adenosine Diphosphate 15-18 purinergic receptor P2Y12 Homo sapiens 101-106 23490430-2 2013 ADP induces platelet aggregation through two purinergic receptors P2Y1 and P2Y12. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 75-80 23490430-9 2013 Under P2Y1 blockade, citalopram inhibited platelet aggregation and integrin alphaIIbbeta3 activation in response to ADP, indicating that citalopram inhibited P2Y12-mediated aggregation. Adenosine Diphosphate 116-119 purinergic receptor P2Y12 Homo sapiens 158-163 23490430-12 2013 Taken together, under the stimulation of ADP, SSRIs inhibit the amplification of platelet aggregation secondary to the activation of P2Y12 receptor, and subsequently reduce the activation of the downstream molecules of the outside-in signaling pathways. Adenosine Diphosphate 41-44 purinergic receptor P2Y12 Homo sapiens 133-138 23093496-7 2013 The potency at P2Y(12) was 2-(methylthio)-ADP > 2-(methylthio)-ATP > ADP > ATP. Adenosine Diphosphate 42-45 purinergic receptor P2Y12 Homo sapiens 15-22 23751441-4 2013 Although the pattern of defective ADP-induced platelet aggregation in MPN suggests an abnormality in the P2Y12 pathway, no previous studies have specifically evaluated P2Y12 function in MPN or the relationship between P2Y12 function and the JAK2V617F mutation. Adenosine Diphosphate 34-37 purinergic receptor P2Y12 Homo sapiens 105-110 22879063-2 2013 P2Y(1) and P2Y(12) both respond to ADP, but while P2Y(1) links to PLC and elevates cytosolic Ca(2+) concentration, P2Y(12) negatively couples to adenylate cyclase, maintaining cAMP at low level. Adenosine Diphosphate 35-38 purinergic receptor P2Y12 Homo sapiens 11-18 22879063-4 2013 During prolonged serum deprivation, cell growth is arrested, the expression of the P2Y(1) receptor strongly decreases and P2Y(12) becomes a major player responsible for ADP-evoked signal transduction. Adenosine Diphosphate 169-172 purinergic receptor P2Y12 Homo sapiens 122-129 22757746-1 2013 The VerifyNow P2Y12 test is a whole-blood, light transmission-based optical detection assay that measures adenosine diphosphate-induced platelet aggregation in a cartridge containing fibrinogen-coated beads. Adenosine Diphosphate 106-127 purinergic receptor P2Y12 Homo sapiens 14-19 23216528-8 2013 Adenosine diphosphate (ADP) induced platelet reactivity was determined by VerifyNow P2Y12 assay, by light transmission aggregometry (LTA) and by multiple electrode impedance aggregometry (MEIA; Multiplate analyser). Adenosine Diphosphate 0-21 purinergic receptor P2Y12 Homo sapiens 85-90 23216528-8 2013 Adenosine diphosphate (ADP) induced platelet reactivity was determined by VerifyNow P2Y12 assay, by light transmission aggregometry (LTA) and by multiple electrode impedance aggregometry (MEIA; Multiplate analyser). Adenosine Diphosphate 23-26 purinergic receptor P2Y12 Homo sapiens 85-90 23472176-6 2013 In contrast, selective P2Y12 agonists ADP and 2-MeS-ADP induced specific calcium flux in cells expressing P2Y12+ Galpha16. Adenosine Diphosphate 38-41 purinergic receptor P2Y12 Homo sapiens 23-28 23472176-6 2013 In contrast, selective P2Y12 agonists ADP and 2-MeS-ADP induced specific calcium flux in cells expressing P2Y12+ Galpha16. Adenosine Diphosphate 38-41 purinergic receptor P2Y12 Homo sapiens 106-111 23594617-1 2013 OBJECTIVE: The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS). Adenosine Diphosphate 58-79 purinergic receptor P2Y12 Homo sapiens 21-26 23594617-1 2013 OBJECTIVE: The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS). Adenosine Diphosphate 81-84 purinergic receptor P2Y12 Homo sapiens 21-26 23093496-12 2013 This study showed that, in addition to ADP and ATP, other ATP derivatives are not only ligands of P2Y(12) but also agonists. Adenosine Diphosphate 39-42 purinergic receptor P2Y12 Homo sapiens 98-105 23083103-0 2012 Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. Adenosine Diphosphate 104-107 purinergic receptor P2Y12 Homo sapiens 72-77 22628078-10 2012 Docking of FPP in a P2Y12 receptor model revealed molecular similarities with ADP and a good fit into the binding pocket for ADP. Adenosine Diphosphate 78-81 purinergic receptor P2Y12 Homo sapiens 20-25 22689668-1 2012 BACKGROUND: The interaction of adenosine diphosphate with its P2Y(1) and P2Y(12) receptors on platelets is important for platelet function. Adenosine Diphosphate 31-52 purinergic receptor P2Y12 Homo sapiens 73-80 22852789-6 2012 Using this technique, we confirmed the primacy of continuous signaling by the ADP autocrine loop acting on P2Y12 in the maintenance of thrombus stability. Adenosine Diphosphate 78-81 purinergic receptor P2Y12 Homo sapiens 107-112 22459907-1 2012 INTRODUCTION: Clopidogrel inhibits ADP mediated platelet aggregation through inhibition of the P2Y12 receptor by its active metabolite. Adenosine Diphosphate 35-38 purinergic receptor P2Y12 Homo sapiens 95-100 22628078-10 2012 Docking of FPP in a P2Y12 receptor model revealed molecular similarities with ADP and a good fit into the binding pocket for ADP. Adenosine Diphosphate 125-128 purinergic receptor P2Y12 Homo sapiens 20-25 22183178-4 2012 An essential part in the platelet activation process is the interaction of adenosine diphosphate (ADP) with the platelet P2Y12 receptor. Adenosine Diphosphate 75-96 purinergic receptor P2Y12 Homo sapiens 121-126 22155453-6 2012 A correlation between platelet binding of 9E18 and P-selectin exposure was observed in patients experiencing coronary artery disease, and antagonists of the ADP receptor P2Y12 limited ADP-induced GPVI dimerization. Adenosine Diphosphate 157-160 purinergic receptor P2Y12 Homo sapiens 170-175 22075250-8 2012 Whereas Rap1 signaling directly controls sustained Rac1 activation, Rac1 affects CalDAG-GEFI- and P2Y12-dependent Rap1 activation via its role in calcium mobilization and granule/ADP release, respectively. Adenosine Diphosphate 179-182 purinergic receptor P2Y12 Homo sapiens 98-103 21979433-8 2012 Both in the presence and absence of ADP inhibition of the purinergic receptor P2Y(12) but not P2Y(1) decreased the cell association of apoA-I and HDL. Adenosine Diphosphate 36-39 purinergic receptor P2Y12 Homo sapiens 58-85 21979433-11 2012 CONCLUSIONS: Binding of apoA-I to ectopic F(0)F(1) ATPase triggers the generation of ADP, which via activation of the purinergic receptor P2Y(12) stimulates the uptake and transport of HDL and initially lipid-free apoA-I by endothelial cells. Adenosine Diphosphate 85-88 purinergic receptor P2Y12 Homo sapiens 118-145 22183178-4 2012 An essential part in the platelet activation process is the interaction of adenosine diphosphate (ADP) with the platelet P2Y12 receptor. Adenosine Diphosphate 98-101 purinergic receptor P2Y12 Homo sapiens 121-126 22183178-5 2012 The P2Y12 receptor is the predominant receptor involved in the ADP-stimulated activation of the glycoprotein IIb/IIIa receptor. Adenosine Diphosphate 63-66 purinergic receptor P2Y12 Homo sapiens 4-9 21532533-14 2011 CONCLUSIONS: Compared with the VASP assay, ADP-induced platelet aggregation shows a greater ability to detect a decrease in platelet aggregation after P2Y12 antagonists. Adenosine Diphosphate 43-46 purinergic receptor P2Y12 Homo sapiens 151-156 21713327-10 2011 In conclusion, a patient"s intrinsic platelet response to ADP before exposure to thienopyridines contributes to residual platelet reactivity to ADP despite high level P2Y12 blockade with high-dose clopidogrel or even higher level P2Y12 blockade with prasugrel. Adenosine Diphosphate 58-61 purinergic receptor P2Y12 Homo sapiens 167-172 21713327-10 2011 In conclusion, a patient"s intrinsic platelet response to ADP before exposure to thienopyridines contributes to residual platelet reactivity to ADP despite high level P2Y12 blockade with high-dose clopidogrel or even higher level P2Y12 blockade with prasugrel. Adenosine Diphosphate 58-61 purinergic receptor P2Y12 Homo sapiens 230-235 21479342-0 2011 Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Adenosine Diphosphate 98-119 purinergic receptor P2Y12 Homo sapiens 79-84 21479342-1 2011 P2Y12, one of the two platelet receptors for adenosine diphosphate (ADP), plays a central role in platelet function. Adenosine Diphosphate 45-66 purinergic receptor P2Y12 Homo sapiens 0-5 21479342-1 2011 P2Y12, one of the two platelet receptors for adenosine diphosphate (ADP), plays a central role in platelet function. Adenosine Diphosphate 68-71 purinergic receptor P2Y12 Homo sapiens 0-5 21479342-2 2011 Defects of P2Y12 should be suspected when ADP, even at high concentrations (>=10 microM), is unable to induce full, irreversible platelet aggregation. Adenosine Diphosphate 42-45 purinergic receptor P2Y12 Homo sapiens 11-16 21330475-5 2011 PAR1-activating peptide (PAR1-AP), adenosine diphosphate (via P2Y1/P2Y12), and glycoprotein VI-targeting collagen-related peptide induced massive SDF-1alpha and VEGF but modest PF4 or no endostatin release. Adenosine Diphosphate 35-56 purinergic receptor P2Y12 Homo sapiens 67-72 22746349-1 2012 P2Y12 is an important G protein-coupled receptor that is involved in ADP-induced platelet aggregation, which is essential for normal haemostasis. Adenosine Diphosphate 69-72 purinergic receptor P2Y12 Homo sapiens 0-5 21736422-7 2012 Furthermore, while succinate alone had no effect in the presence of platelet inhibitors, responsiveness of platelets to ADP after pretreatment with P2Y(1) or P2Y(12) antagonists was fully restored, when platelets were co-stimulated with 100 microM succinate. Adenosine Diphosphate 120-123 purinergic receptor P2Y12 Homo sapiens 158-165 21621250-4 2011 PATIENTS AND METHODS: Adenosine diphosphate (ADP)-inducible platelet reactivity was assessed by light transmission aggregometry (LTA), the VerifyNow P2Y12 assay, the vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay, multiple electrode aggregometry (MEA), and the Impact-R in 288 patients after angioplasty and stenting for cardiovascular disease. Adenosine Diphosphate 22-43 purinergic receptor P2Y12 Homo sapiens 149-154 21621250-4 2011 PATIENTS AND METHODS: Adenosine diphosphate (ADP)-inducible platelet reactivity was assessed by light transmission aggregometry (LTA), the VerifyNow P2Y12 assay, the vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay, multiple electrode aggregometry (MEA), and the Impact-R in 288 patients after angioplasty and stenting for cardiovascular disease. Adenosine Diphosphate 45-48 purinergic receptor P2Y12 Homo sapiens 149-154 21572491-2 2011 The interaction of ADP with its platelet receptor P2Y12 plays a crucial role in platelet activation and thrombogenesis. Adenosine Diphosphate 19-22 purinergic receptor P2Y12 Homo sapiens 50-55 21392598-3 2011 Increased bleeding with dual antiplatelet therapy can be attributed to blockade of the thromboxane A(2) (by aspirin) and adenosine diphosphate (by P2Y(12) antagonist) platelet activation pathways that are essential to hemostasis. Adenosine Diphosphate 121-142 purinergic receptor P2Y12 Homo sapiens 147-154 21136013-1 2011 We have recently shown that ADP-induced activation of protein kinase C (PKC) requires the co-stimulation of both P2Y1 and P2Y12 receptors. Adenosine Diphosphate 28-31 purinergic receptor P2Y12 Homo sapiens 122-127 21216445-0 2011 Identification of P2Y12 single-nucleotide polymorphisms and their influences on the variation in ADP-induced platelet aggregation. Adenosine Diphosphate 97-100 purinergic receptor P2Y12 Homo sapiens 18-23 21216445-5 2011 The effects of genetic variation in the P2Y12 gene on the extent of ADP-induced platelet aggregation were studied in healthy Korean men (n=40). Adenosine Diphosphate 68-71 purinergic receptor P2Y12 Homo sapiens 40-45 21216445-8 2011 Genetic analysis of the P2Y12 SNPs and haplotypes revealed a statistically significant association between P2Y12 haplotype, denoted H3, and an increase in the ADP-induced platelet aggregation response relative to that for the reference haplotype H1 (P=0.01). Adenosine Diphosphate 159-162 purinergic receptor P2Y12 Homo sapiens 24-29 21216445-8 2011 Genetic analysis of the P2Y12 SNPs and haplotypes revealed a statistically significant association between P2Y12 haplotype, denoted H3, and an increase in the ADP-induced platelet aggregation response relative to that for the reference haplotype H1 (P=0.01). Adenosine Diphosphate 159-162 purinergic receptor P2Y12 Homo sapiens 107-112 21136013-2 2011 In this work, we show that inhibition of ADP-mediated phosphorylation of pleckstrin, the main PKC substrate, caused by antagonists of the P2Y12 receptor can be reversed by stimulation of the alpha2-adrenergic receptor by epinephrine. Adenosine Diphosphate 41-44 purinergic receptor P2Y12 Homo sapiens 138-143 21106949-0 2011 Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Adenosine Diphosphate 23-26 purinergic receptor P2Y12 Homo sapiens 101-106 20966167-0 2011 The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Adenosine Diphosphate 32-53 purinergic receptor P2Y12 Homo sapiens 13-18 20966167-1 2011 P2Y12, the G(i)-coupled platelet receptor for adenosine diphosphate (ADP), plays a central role in platelet function. Adenosine Diphosphate 46-67 purinergic receptor P2Y12 Homo sapiens 0-5 20966167-1 2011 P2Y12, the G(i)-coupled platelet receptor for adenosine diphosphate (ADP), plays a central role in platelet function. Adenosine Diphosphate 69-72 purinergic receptor P2Y12 Homo sapiens 0-5 20966167-3 2011 Defects of P2Y12 should be suspected when ADP, even at high concentrations (>= 10 muM), is unable to induce full, irreversible platelet aggregation. Adenosine Diphosphate 42-45 purinergic receptor P2Y12 Homo sapiens 11-16 21106949-3 2011 In the presence of a P2Y12 antagonist, preincubation of PRP with ADP inhibited aggregation; this effect was abolished by adenosine deaminase. Adenosine Diphosphate 65-68 purinergic receptor P2Y12 Homo sapiens 21-26 21106949-7 2011 CONCLUSIONS: ADP inhibits platelet aggregation in the presence of a P2Y12 antagonist through conversion to adenosine. Adenosine Diphosphate 13-16 purinergic receptor P2Y12 Homo sapiens 68-73 21467700-3 2011 METHODS: We measured the ability of 20 microM ADP to aggregate platelets using the VerifyNow P2Y12 Assay. Adenosine Diphosphate 46-49 purinergic receptor P2Y12 Homo sapiens 93-98 21231822-2 2011 The P2Y12 receptor, activated by ADP, plays a central role in platelet activation and thrombus formation. Adenosine Diphosphate 33-36 purinergic receptor P2Y12 Homo sapiens 4-9 20177818-1 2010 The interaction of ADP with its platelet receptor P2Y12 plays a crucial role in platelet activation and thrombogenesis. Adenosine Diphosphate 19-22 purinergic receptor P2Y12 Homo sapiens 50-55 21071695-8 2010 CONCLUSIONS: These data suggest that the P2Y12 receptor not only is central to ADP-induced platelet activation but also may mediate platelet-independent responses, specifically under conditions of enhanced thrombin formation, such as local vessel injury and atherosclerotic plaque rupture. Adenosine Diphosphate 79-82 purinergic receptor P2Y12 Homo sapiens 41-46 20977287-5 2010 On the other hand, thienopyridines suppress the platelet aggregation adenosine diphosphate (ADP) pathway by inhibiting the platelet P2Y12 subtype of the ADP receptor. Adenosine Diphosphate 69-90 purinergic receptor P2Y12 Homo sapiens 132-137 20977287-5 2010 On the other hand, thienopyridines suppress the platelet aggregation adenosine diphosphate (ADP) pathway by inhibiting the platelet P2Y12 subtype of the ADP receptor. Adenosine Diphosphate 92-95 purinergic receptor P2Y12 Homo sapiens 132-137 22022533-6 2011 The platelet antagonists [cangrelor, MRS2179, and apyrase] inhibited 59M cell induced activation suggesting a P2Y12 and P2Y1 receptor mediated mechanism of platelet activation dependent on the release of ADP by 59M cells. Adenosine Diphosphate 204-207 purinergic receptor P2Y12 Homo sapiens 110-115 20977463-2 2010 Concentrations of nucleotides such as ADP, the physiological agonist at platelet P2Y1 and P2Y12 receptors, are regulated by vascular ectonucleotidases, mainly nucleoside triphosphate diphosphohydrolase (NTPDase)1 and ecto-5"-nucleotidase. Adenosine Diphosphate 38-41 purinergic receptor P2Y12 Homo sapiens 90-95 20210760-2 2010 In vivo, activated platelets release adenosine diphosphate (ADP), whose binding to the platelet P2Y12 receptor elicits progressive and sustained platelet aggregation. Adenosine Diphosphate 37-58 purinergic receptor P2Y12 Homo sapiens 96-101 20681951-0 2010 TGF-beta and LPS modulate ADP-induced migration of microglial cells through P2Y1 and P2Y12 receptor expression. Adenosine Diphosphate 26-29 purinergic receptor P2Y12 Homo sapiens 85-90 20681951-5 2010 Then, we found that migratory capability and expression of both P2Y receptors were abrogated in microglial cells from LPS-stimulated mixed glial cultures, while TGF-beta increased ADP-induced migration and the expression of P2Y12 and P2Y1 receptors. Adenosine Diphosphate 180-183 purinergic receptor P2Y12 Homo sapiens 224-229 20664906-5 2010 The reference test was P2Y12 receptor occupancy, measured by binding of 33P-2MeS-ADP to platelets. Adenosine Diphosphate 81-84 purinergic receptor P2Y12 Homo sapiens 23-28 20210760-2 2010 In vivo, activated platelets release adenosine diphosphate (ADP), whose binding to the platelet P2Y12 receptor elicits progressive and sustained platelet aggregation. Adenosine Diphosphate 60-63 purinergic receptor P2Y12 Homo sapiens 96-101 20653328-2 2010 Since adenosine diphosphate (ADP) represents one of the most important mediators of thrombosis, the inhibition of the platelet ADP receptor, in particular the P2Y12 subtype, plays a pivotal role in secondary prevention of recurrent atherothrombotic events in high-risk settings. Adenosine Diphosphate 6-27 purinergic receptor P2Y12 Homo sapiens 159-164 20653328-2 2010 Since adenosine diphosphate (ADP) represents one of the most important mediators of thrombosis, the inhibition of the platelet ADP receptor, in particular the P2Y12 subtype, plays a pivotal role in secondary prevention of recurrent atherothrombotic events in high-risk settings. Adenosine Diphosphate 29-32 purinergic receptor P2Y12 Homo sapiens 159-164 20031628-9 2009 The size of this effect per haplotype allele was approximately 5% aggregation in the ADP-induced light-transmittance aggregometry (P<0.05) and 11 P2Y12 reaction units in the VerifyNow P2Y12 assay (P<0.05). Adenosine Diphosphate 85-88 purinergic receptor P2Y12 Homo sapiens 187-192 19818001-6 2010 RESULTS: ADP-inducible platelet reactivity increased linearly with age after adjustment for cardiovascular risk factors, type of intervention, medication, C-reactive protein (CRP) and renal function [using LTA 0.36% of maximal aggregation per year, 95% CI 0.08-0.64%, P = 0.013; using the VerifyNow P2Y12 assay 3.2 P2Y12 reaction units (PRU) per year, 95% CI 1.98-4.41 PRU, P < 0.001]. Adenosine Diphosphate 9-12 purinergic receptor P2Y12 Homo sapiens 299-304 19818001-6 2010 RESULTS: ADP-inducible platelet reactivity increased linearly with age after adjustment for cardiovascular risk factors, type of intervention, medication, C-reactive protein (CRP) and renal function [using LTA 0.36% of maximal aggregation per year, 95% CI 0.08-0.64%, P = 0.013; using the VerifyNow P2Y12 assay 3.2 P2Y12 reaction units (PRU) per year, 95% CI 1.98-4.41 PRU, P < 0.001]. Adenosine Diphosphate 9-12 purinergic receptor P2Y12 Homo sapiens 315-320 19818001-7 2010 ADP-inducible platelet reactivity was significantly higher in patients aged 75 years or older compared with younger patients (P = 0.003 for LTA and P < 0.001 for the VerifyNow P2Y12 assay). Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 179-184 19818001-8 2010 Further, high on-treatment residual ADP-inducible platelet reactivity was significantly more common among patients aged 75 years or older (P = 0.02 for LTA and P < 0.001 for the VerifyNow P2Y12 assay). Adenosine Diphosphate 36-39 purinergic receptor P2Y12 Homo sapiens 191-196 19822647-5 2009 P2Y12 receptor expression by LAD2 cells is required for competition between radiolabeled ADP and unlabeled LTE4 but not for direct binding of LTE4, suggesting that P2Y12 complexes with another receptor to recognize LTE4. Adenosine Diphosphate 89-92 purinergic receptor P2Y12 Homo sapiens 0-5 19822647-5 2009 P2Y12 receptor expression by LAD2 cells is required for competition between radiolabeled ADP and unlabeled LTE4 but not for direct binding of LTE4, suggesting that P2Y12 complexes with another receptor to recognize LTE4. Adenosine Diphosphate 89-92 purinergic receptor P2Y12 Homo sapiens 164-169 19733667-2 2009 Extracellular ADP was reported to induce microglia chemotaxis and membrane ruffles through P2Y12 receptor. Adenosine Diphosphate 14-17 purinergic receptor P2Y12 Homo sapiens 91-96 19552634-10 2009 CONCLUSIONS: These data indicate that P2Y(12) is targeted by ticagrelor via a mechanism that is non-competitive with ADP, suggesting the existence of an independent receptor-binding site for CPTPs. Adenosine Diphosphate 117-120 purinergic receptor P2Y12 Homo sapiens 38-45 19630813-6 2009 Ticagrelor is the first of a new class of orally available antiplatelet agents antagonizing the effects of ADP mediated by P2Y12; it is currently being studied in a phase III trial in patients with ACS. Adenosine Diphosphate 107-110 purinergic receptor P2Y12 Homo sapiens 123-128 19476973-0 2009 Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy. Adenosine Diphosphate 70-73 purinergic receptor P2Y12 Homo sapiens 95-100 19604122-5 2009 Cangrelor is a potent, competitive inhibitor of the P2Y12 receptor that is administered by intravenous infusion and rapidly achieves near complete inhibition of ADP-induced platelet aggregation. Adenosine Diphosphate 161-164 purinergic receptor P2Y12 Homo sapiens 52-57 18213371-1 2008 BACKGROUND AND AIMS: The aims of this study were to investigate (1) if P2Y(12) polymorphisms defining the P2Y(12) H2 allele are associated with any other SNPs that may explain the previously reported association with increased ADP induced platelet activation and association with peripheral arterial disease and coronary artery disease and (2) if such variants are associated with acute myocardial infarction (AMI) or classical risk factors for AMI. Adenosine Diphosphate 227-230 purinergic receptor P2Y12 Homo sapiens 71-78 19346255-1 2009 ADP plays an integral role in the process of hemostasis by signaling through two platelet G-protein-coupled receptors, P2Y1 and P2Y12. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 128-133 19346255-3 2009 Specifically, the results have indicated that although P2Y1 receptors are involved in the initiation of platelet aggregation, P2Y12 receptor activation appears to account for the bulk of the ADP-mediated effects. Adenosine Diphosphate 191-194 purinergic receptor P2Y12 Homo sapiens 126-131 18755689-2 2008 We found that ADP-induced phosphorylation of pleckstrin, the main platelet substrate for PKC, was completely inhibited not only by an antagonist of the G(q)-coupled P2Y1 receptor but also upon blockade of the G(i)-coupled P2Y12 receptor. Adenosine Diphosphate 14-17 purinergic receptor P2Y12 Homo sapiens 222-227 18183622-2 2008 We previously reported that ATP/ADP promotes microglial chemotaxis via the Gi/o-coupled P2Y12 receptor; however, the intracellular signaling underlying P2Y12-receptor-mediated microglial chemotaxis is not fully understood. Adenosine Diphosphate 32-35 purinergic receptor P2Y12 Homo sapiens 88-93 18183622-2 2008 We previously reported that ATP/ADP promotes microglial chemotaxis via the Gi/o-coupled P2Y12 receptor; however, the intracellular signaling underlying P2Y12-receptor-mediated microglial chemotaxis is not fully understood. Adenosine Diphosphate 32-35 purinergic receptor P2Y12 Homo sapiens 152-157 18183622-6 2008 ADP stimulation induced Akt phosphorylation in microglia, and the phosphorylation was inhibited by a P2Y12 receptor antagonist, AR-C69931MX. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 101-106 19118249-10 2009 CONCLUSIONS: RPR to ADP with clopidogrel therapy, measured by the point-of-care assay VerifyNow P2Y12, is able to detect acute coronary syndrome patients at risk of 12-month cardiovascular death and nonfatal MI. Adenosine Diphosphate 20-23 purinergic receptor P2Y12 Homo sapiens 96-101 18232657-2 2008 We discovered that modification of natural and synthetic dinucleoside polyphosphates and nucleotides with lipophilic substituents on the ribose and base conferred P2Y12 receptor antagonist properties to these molecules producing potent inhibitors of ADP-mediated platelet aggregation. Adenosine Diphosphate 250-253 purinergic receptor P2Y12 Homo sapiens 163-168 18064324-5 2007 There was no spontaneous aggregation in PRP but ADP-induced aggregation was enhanced at 28 degrees C. The P2Y12 antagonist AR-C69931 inhibited all spontaneous aggregation at 28 degrees C and reduced all ADP-induced aggregation responses to small, reversible responses. Adenosine Diphosphate 48-51 purinergic receptor P2Y12 Homo sapiens 106-111 17803810-2 2007 The H2 haplotype of the P2Y12 receptor gene (P2RY12) has been found to be associated with maximal aggregation response to adenosine diphosphate (ADP) and with increased risk for peripheral arterial disease. Adenosine Diphosphate 122-143 purinergic receptor P2Y12 Homo sapiens 24-29 17803810-2 2007 The H2 haplotype of the P2Y12 receptor gene (P2RY12) has been found to be associated with maximal aggregation response to adenosine diphosphate (ADP) and with increased risk for peripheral arterial disease. Adenosine Diphosphate 122-143 purinergic receptor P2Y12 Homo sapiens 45-51 17803810-2 2007 The H2 haplotype of the P2Y12 receptor gene (P2RY12) has been found to be associated with maximal aggregation response to adenosine diphosphate (ADP) and with increased risk for peripheral arterial disease. Adenosine Diphosphate 145-148 purinergic receptor P2Y12 Homo sapiens 24-29 17803810-2 2007 The H2 haplotype of the P2Y12 receptor gene (P2RY12) has been found to be associated with maximal aggregation response to adenosine diphosphate (ADP) and with increased risk for peripheral arterial disease. Adenosine Diphosphate 145-148 purinergic receptor P2Y12 Homo sapiens 45-51 18495218-1 2008 ADP plays a key role in platelet aggregation which has led to the development of antiplatelet drugs that target the P2Y12 receptor. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 116-121 18539312-2 2008 The key role that ADP plays in this process has led to the development of antiplatelet drugs that target the P2Y12 receptor. Adenosine Diphosphate 18-21 purinergic receptor P2Y12 Homo sapiens 109-114 18064324-5 2007 There was no spontaneous aggregation in PRP but ADP-induced aggregation was enhanced at 28 degrees C. The P2Y12 antagonist AR-C69931 inhibited all spontaneous aggregation at 28 degrees C and reduced all ADP-induced aggregation responses to small, reversible responses. Adenosine Diphosphate 203-206 purinergic receptor P2Y12 Homo sapiens 106-111 16990590-4 2007 Here, we show that ADP secreted from platelet-dense granules, and subsequent activation of P2Y12 receptors, as well as TxA2 release are important upstream mediators of p38 MAP kinase activation by thrombin. Adenosine Diphosphate 19-22 purinergic receptor P2Y12 Homo sapiens 91-96 17200114-6 2007 p38 phosphorylation was dependent on ADP signaling through P2Y12, its receptor. Adenosine Diphosphate 37-40 purinergic receptor P2Y12 Homo sapiens 59-64 17298299-1 2007 We have previously shown that ADP-induced thromboxane generation in platelets requires signalling events from the G(q)-coupled P2Y1 receptor (platelet ADP receptor coupled to stimulation of phospholipase C) and the G(i)-coupled P2Y12 receptor (platelet ADP receptor coupled to inhibition of adenylate cyclase) in addition to outside-in signalling. Adenosine Diphosphate 30-33 purinergic receptor P2Y12 Homo sapiens 228-233 17298299-5 2007 However, blockade of either P2Y1 or the P2Y12 receptors with corresponding antagonists completely abolished ERK phosphorylation, indicating that both P2Y receptors are required for ADP-induced ERK activation. Adenosine Diphosphate 181-184 purinergic receptor P2Y12 Homo sapiens 40-45 17187456-1 2007 Platelets possess three P2 receptors for adenine nucleotides: P2Y1 and P2Y12, which interact with ADP, and P2X1, which interacts with ATP. Adenosine Diphosphate 98-101 purinergic receptor P2Y12 Homo sapiens 71-76 16804093-5 2006 These results were paralleled in human platelets, in which PMA reduced subsequent ADP-induced P2Y1 and P2Y12 receptor signaling. Adenosine Diphosphate 82-85 purinergic receptor P2Y12 Homo sapiens 103-108 16563469-1 2007 INTRODUCTION: Clopidogrel inhibits platelet P2Y12 ADP receptors, while ADP, as an inductor of aggregation, stimulates both P2Y12 and P2Y1 platelet receptors. Adenosine Diphosphate 50-53 purinergic receptor P2Y12 Homo sapiens 44-49 16563469-4 2007 ADP is used to maximally activate the platelets by binding to the P2Y1 and P2Y12 platelet receptors, while PGE1 is used to suppress the ADP-induced P2Y1-mediated increase in intracellular calcium levels. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 75-80 17066149-1 2006 The interaction of adenosine-5"-diphosphate (ADP) with its platelet receptors (P2Y1 and P2Y12) plays a very important role in thrombogenesis. Adenosine Diphosphate 19-43 purinergic receptor P2Y12 Homo sapiens 88-93 17066149-1 2006 The interaction of adenosine-5"-diphosphate (ADP) with its platelet receptors (P2Y1 and P2Y12) plays a very important role in thrombogenesis. Adenosine Diphosphate 45-48 purinergic receptor P2Y12 Homo sapiens 88-93 16843179-14 2006 CONCLUSIONS: The P2Y12-dependent and -independent pathways of platelet reactivity are altered in T2DM compared with nondiabetic patients, and ITDM have greater ADP-induced platelet aggregation compared with NITDM. Adenosine Diphosphate 160-163 purinergic receptor P2Y12 Homo sapiens 17-22 16706985-12 2006 CONCLUSIONS: Our data indicate that the continuous interaction between released ADP and P2Y12 is critical for the maintenance of alpha(IIb)beta3 activation. Adenosine Diphosphate 80-83 purinergic receptor P2Y12 Homo sapiens 88-93 17111196-1 2006 BACKGROUND: P2Y12 is the major platelet receptor that mediates ADP-induced aggregation. Adenosine Diphosphate 63-66 purinergic receptor P2Y12 Homo sapiens 12-17 17139371-11 2006 These six subjects showed the lowest ADP EC50 values in the absence of the drug, possibly reflecting high sensitivity of their platelet P2Y12 receptors to ADP. Adenosine Diphosphate 37-40 purinergic receptor P2Y12 Homo sapiens 136-141 17139371-11 2006 These six subjects showed the lowest ADP EC50 values in the absence of the drug, possibly reflecting high sensitivity of their platelet P2Y12 receptors to ADP. Adenosine Diphosphate 155-158 purinergic receptor P2Y12 Homo sapiens 136-141 17059469-5 2006 ADP acts through two G protein-coupled receptors, the Gq-coupled P2Y1 receptor, and the Gi-coupled P2Y12 receptor. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 99-104 17059469-9 2006 Furthermore, costimulation of both P2Y1 and P2Y12 receptors is required for ADP-induced platelet aggregation. Adenosine Diphosphate 76-79 purinergic receptor P2Y12 Homo sapiens 44-49 16934758-0 2006 Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors. Adenosine Diphosphate 50-53 purinergic receptor P2Y12 Homo sapiens 74-79 16941047-1 2006 The interaction of adenosine-5"-diphosphate (ADP) with its platelet receptors (P2Y(1) and P2Y(12)) plays a very important role in thrombogenesis. Adenosine Diphosphate 19-43 purinergic receptor P2Y12 Homo sapiens 90-97 16941047-1 2006 The interaction of adenosine-5"-diphosphate (ADP) with its platelet receptors (P2Y(1) and P2Y(12)) plays a very important role in thrombogenesis. Adenosine Diphosphate 45-48 purinergic receptor P2Y12 Homo sapiens 90-97 16634757-1 2006 Adenosine diphosphate (ADP) initiates and maintains sustained aggregation of platelets through simultaneous activation of both the Gq-coupled P2Y1 receptor and the Gi-coupled P2Y12 receptor. Adenosine Diphosphate 0-21 purinergic receptor P2Y12 Homo sapiens 175-180 16634757-1 2006 Adenosine diphosphate (ADP) initiates and maintains sustained aggregation of platelets through simultaneous activation of both the Gq-coupled P2Y1 receptor and the Gi-coupled P2Y12 receptor. Adenosine Diphosphate 23-26 purinergic receptor P2Y12 Homo sapiens 175-180 16154027-8 2005 Finally, the H1/H2 polymorphism of the platelet ADP receptor P2Y12 gene has been associated with ADP-induced platelet aggregation response and peripheral arterial disease. Adenosine Diphosphate 48-51 purinergic receptor P2Y12 Homo sapiens 61-66 16515502-3 2006 Two receptors for ADP, the G(q)-protein-coupled P2Y1 and G(i)-protein-coupled P2Y12 and one receptor for ATP, the P2X1 ion channel, have been identified on platelets. Adenosine Diphosphate 18-21 purinergic receptor P2Y12 Homo sapiens 78-83 16236603-1 2005 ADP activates human platelets through two G-protein coupled receptors, P2Y1 and P2Y12, to induce a range of functional responses. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 80-85 16236603-2 2005 Here we have addressed the role and mechanism of P2Y12 in modulating ADP-induced platelet shape change. Adenosine Diphosphate 69-72 purinergic receptor P2Y12 Homo sapiens 49-54 16236603-7 2005 We conclude that P2Y12 plays a potentiatory role in ADP-induced shape change through regulation of the Rho kinase pathway, potentiating both myosin phosphorylation and actin polymerisation, and this forms part of an important signalling pathway additional to its well-established Gi-coupled pathways. Adenosine Diphosphate 52-55 purinergic receptor P2Y12 Homo sapiens 17-22 16194206-6 2005 Conversely, secreted ADP strongly potentiated Rac activation induced by FcgammaRIIa clustering or TRAP via its P2Y12 receptor, the target of antithrombotic thienopyridines. Adenosine Diphosphate 21-24 purinergic receptor P2Y12 Homo sapiens 111-116 16194207-8 2005 Our data suggest that secretion of endogenous ADP and subsequent P2Y12-mediated signaling are critical for platelet aggregation, platelet spreading, and as a consequence, for stabilization of thrombus. Adenosine Diphosphate 46-49 purinergic receptor P2Y12 Homo sapiens 65-70 16339499-1 2006 OBJECTIVE: ADP-induced P2y12 signaling is crucial for formation and stabilization of an arterial thrombus. Adenosine Diphosphate 11-14 purinergic receptor P2Y12 Homo sapiens 23-28 16228296-6 2005 Since it is known that ADP stimulates the PI3K and calcium signal primarily through P2Y12 and P2Y1 receptors respectively, our data indicated that integrin alpha(IIb)beta3 downstream PI3K and calcium activation might be not completely coupled to integrin associated signaling complex, but in part through feedback stimulation by granular released ADP. Adenosine Diphosphate 23-26 purinergic receptor P2Y12 Homo sapiens 84-89 15920726-5 2005 In the present study, we report that the ADP-induced chemotaxis of microglia is mediated by P2Y12/13 receptors and is beta1 integrin-dependent in the presence of fibronectin. Adenosine Diphosphate 41-44 purinergic receptor P2Y12 Homo sapiens 92-97 16268477-3 2005 In the present study, we determined the stereoselectivity of P2Y12 antagonist effects by assessing the antagonism of the [3H]-2-MeS-ADP that binds to human P2Y12 receptors expressed in Chinese hamster ovary cells as an affinity assay, and by the inhibition of ADP-induced aggregation of washed human platelets as a functional assay. Adenosine Diphosphate 132-135 purinergic receptor P2Y12 Homo sapiens 61-66 16268477-3 2005 In the present study, we determined the stereoselectivity of P2Y12 antagonist effects by assessing the antagonism of the [3H]-2-MeS-ADP that binds to human P2Y12 receptors expressed in Chinese hamster ovary cells as an affinity assay, and by the inhibition of ADP-induced aggregation of washed human platelets as a functional assay. Adenosine Diphosphate 132-135 purinergic receptor P2Y12 Homo sapiens 156-161 15863506-12 2005 However, accumulation of GTP-bound Rap1B in platelets activated by co-stimulation of cMpl and P2Y12 receptor was identical to that induced by the simultaneous ligation of P2Y1 and P2Y12 receptor by ADP. Adenosine Diphosphate 198-201 purinergic receptor P2Y12 Homo sapiens 180-185 15665114-0 2005 P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Adenosine Diphosphate 29-32 purinergic receptor P2Y12 Homo sapiens 9-14 15333577-5 2004 Whereas TXA2 has minimal effects, released ADP via only P2Y12 potentiates platelet adhesion to the octapeptide. Adenosine Diphosphate 43-46 purinergic receptor P2Y12 Homo sapiens 56-61 15869601-0 2005 Lipid rafts are required in Galpha(i) signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation. Adenosine Diphosphate 88-91 purinergic receptor P2Y12 Homo sapiens 66-71 15869601-3 2005 We sought to determine the importance of lipid rafts in ADP-mediated platelet activation via the G protein-coupled P2Y1 and P2Y12 receptors using lipid raft disruption by cholesterol depletion with methyl-beta-cyclodextrin. Adenosine Diphosphate 56-59 purinergic receptor P2Y12 Homo sapiens 124-129 15795539-3 2005 The aim of this study was to test in patients (n = 416) scheduled for coronary artery stenting whether P2Y12 haplotype H2 carriage is associated with increased ADP-induced platelet aggregation after administration of a 600 mg loading dose of clopidogrel. Adenosine Diphosphate 160-163 purinergic receptor P2Y12 Homo sapiens 103-108 15795539-2 2005 Recently, a P2Y12 haplotype was shown to be associated with enhanced adenosine diphosphate (ADP)-induced platelet aggregation in healthy volunteers. Adenosine Diphosphate 69-90 purinergic receptor P2Y12 Homo sapiens 12-17 15795539-2 2005 Recently, a P2Y12 haplotype was shown to be associated with enhanced adenosine diphosphate (ADP)-induced platelet aggregation in healthy volunteers. Adenosine Diphosphate 92-95 purinergic receptor P2Y12 Homo sapiens 12-17 15602005-3 2005 Plasma membranes from ADP-stimulated platelets also retained P2Y12 activity. Adenosine Diphosphate 22-25 purinergic receptor P2Y12 Homo sapiens 61-66 15345752-1 2004 ADP is the cognate agonist of the P2Y1, P2Y12, and P2Y13 receptors. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 40-45 15308557-1 2004 OBJECTIVE: ADP plays an important role in platelet aggregation by activating P2Y12 receptors. Adenosine Diphosphate 11-14 purinergic receptor P2Y12 Homo sapiens 77-82 15308557-8 2004 The contraction was not reduced in patients using clopidogrel, a drug inhibiting ADP-induced platelet aggregation by blocking the P2Y12 receptor. Adenosine Diphosphate 81-84 purinergic receptor P2Y12 Homo sapiens 130-135 15308557-10 2004 CONCLUSIONS: ADP acting on P2Y12 receptors not only is important for platelet activation but also stimulates vasoconstriction. Adenosine Diphosphate 13-16 purinergic receptor P2Y12 Homo sapiens 27-32 14610915-1 2003 With the cloning of the P2Y12 receptor, the molecular basis for ADP-induced platelet aggregation is seemingly complete. Adenosine Diphosphate 64-67 purinergic receptor P2Y12 Homo sapiens 24-29 15213852-10 2004 Stimulating the Gq-coupled TXA2 -receptor with U46619 (10 microM), which leads to ADP secretion and P2Y12 receptor-dependent platelet aggregation, also induces P2Y12-related ERK2 activation. Adenosine Diphosphate 82-85 purinergic receptor P2Y12 Homo sapiens 160-165 15213852-14 2004 Our data indicate that both primary signalling through Gq, which evokes ADP secretion, as well as subsequent coupling via Gi by the P2Y12 receptor are required for ERK2 activation. Adenosine Diphosphate 72-75 purinergic receptor P2Y12 Homo sapiens 132-137 15140134-4 2004 ADP-induced P-selectin expression was inhibited both by MRS 2179 (a P2Y1 selective antagonist) and AR-C69931MX (a P2Y12 selective antagonist), suggesting a role for both Galpha(q) and Galpha(i) pathways in ADP-mediated alpha granule release. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 114-119 15203713-9 2004 We conclude that ADP released from red blood cells enhances PMP formation induced by collagen, and that both P2Y12 and P2Y1 contribute to ADP-potentiation of PMP generation induced by collagen. Adenosine Diphosphate 138-141 purinergic receptor P2Y12 Homo sapiens 109-114 14706855-7 2004 By contrast, U46619 (10 microM), a stable analog of TXA(2), induced ERK2 activation in an ADP-dependent manner, via the P2Y12 receptor. Adenosine Diphosphate 90-93 purinergic receptor P2Y12 Homo sapiens 120-125 14662702-1 2003 BACKGROUND: We recently described a gain-of-function haplotype, called H2, of the adenosine diphosphate (ADP) receptor P2Y12 gene associated with increased ADP-induced platelet aggregation ex vivo in healthy volunteers. Adenosine Diphosphate 105-108 purinergic receptor P2Y12 Homo sapiens 119-124 15265806-0 2004 Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Adenosine Diphosphate 74-77 purinergic receptor P2Y12 Homo sapiens 41-46 15265806-0 2004 Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Adenosine Diphosphate 74-77 purinergic receptor P2Y12 Homo sapiens 56-61 14645014-8 2004 These results indicate a central role for ADP-mediated P2Y1 and P2Y12 receptor activation in supporting LPA-induced platelet aggregation. Adenosine Diphosphate 42-45 purinergic receptor P2Y12 Homo sapiens 64-69 14670370-0 2004 Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Adenosine Diphosphate 14-17 purinergic receptor P2Y12 Homo sapiens 87-92 12913786-2 2003 When platelets become activated by various soluble agonists or by adhesion to subendothelium under high shear, they release adenosine-5"-diphosphate that acts in a positive feedback mechanism on two different G-protein coupled receptors (P2Y(12), P2Y(1)) on platelets. Adenosine Diphosphate 124-148 purinergic receptor P2Y12 Homo sapiens 238-245 12913786-3 2003 This released adenosine-5"-diphosphate, acting through P2Y(12), is critical for sustained aggregation and stabilization of thrombi. Adenosine Diphosphate 14-38 purinergic receptor P2Y12 Homo sapiens 55-62 12913786-5 2003 Recent studies using either inhibitors of key components of signaling pathways or genetically engineered mice have contributed to our understanding of the signaling mechanisms in platelets mediated by adenosine-5"-diphosphate through the P2Y(12) receptor. Adenosine Diphosphate 201-225 purinergic receptor P2Y12 Homo sapiens 238-245 12912815-0 2003 Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Adenosine Diphosphate 0-21 purinergic receptor P2Y12 Homo sapiens 70-75 12912815-8 2003 CONCLUSIONS: In healthy subjects, ADP-induced platelet aggregation is associated with a haplotype of the P2Y12 receptor gene. Adenosine Diphosphate 34-37 purinergic receptor P2Y12 Homo sapiens 105-110 12615691-2 2003 One of the receptors involved in ADP-induced platelet activation is the P2Y12 receptor, which is a target for antithrombotic drugs. Adenosine Diphosphate 33-36 purinergic receptor P2Y12 Homo sapiens 72-77 12615691-9 2003 CONCLUSIONS: These findings demonstrate that ADP and its P2Y12 receptor are involved in thrombus growth and especially in the formation of emboli on the downstream side of the initial thrombus. Adenosine Diphosphate 45-48 purinergic receptor P2Y12 Homo sapiens 57-62 12353080-0 2002 Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Adenosine Diphosphate 14-17 purinergic receptor P2Y12 Homo sapiens 114-119 12578987-6 2003 Neither mutation interfered with receptor surface expression but both altered function, since ADP inhibited the forskolin-induced increase of cAMP markedly less in cells transfected with either mutant P2Y(12) as compared with wild-type receptor. Adenosine Diphosphate 94-97 purinergic receptor P2Y12 Homo sapiens 201-208 12578987-7 2003 These studies delineate a region of P2Y(12) required for normal function after ADP binding. Adenosine Diphosphate 79-82 purinergic receptor P2Y12 Homo sapiens 36-43 11815620-7 2002 By contrast, prevention of ADP binding to the P2Y12 receptor totally suppressed activation of Rap1B without affecting Ca(2+) signaling. Adenosine Diphosphate 27-30 purinergic receptor P2Y12 Homo sapiens 46-51 11950711-11 2002 This suggested that P2Y(12) and P2Y(1) were both involved in platelet adhesion on immobilized fibrinogen, thereby revealing it as ADP dependent. Adenosine Diphosphate 130-133 purinergic receptor P2Y12 Homo sapiens 20-27 12806027-3 2002 Both pharmacological and molecular biological approaches have confirmed the role of the P2Y1 and P2Y12 receptors in the ADP-induced platelet fibrinogen receptor activation. Adenosine Diphosphate 120-123 purinergic receptor P2Y12 Homo sapiens 97-102 12806027-5 2002 Whereas the P2Y12 receptor mediates the potentiation of dense granule release reaction, both the P2Y1 and P2Y12 receptors play an important role in the ADP-induced phospholipase A2 activation. Adenosine Diphosphate 152-155 purinergic receptor P2Y12 Homo sapiens 106-111 11502873-2 2001 ADP-induced platelet aggregation is mediated by two distinct G protein-coupled ADP receptors, Gq-linked P2Y(1), and Gi-linked P2T(AC), which has not been cloned. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 126-133 11756171-1 2002 Adenosine diphosphate (ADP) is a platelet agonist that causes platelet shape change and aggregation as well as generation of thromboxane A(2), another platelet agonist, through its effects on P2Y1, P2Y12, and P2X1 receptors. Adenosine Diphosphate 0-21 purinergic receptor P2Y12 Homo sapiens 198-203 11756171-1 2002 Adenosine diphosphate (ADP) is a platelet agonist that causes platelet shape change and aggregation as well as generation of thromboxane A(2), another platelet agonist, through its effects on P2Y1, P2Y12, and P2X1 receptors. Adenosine Diphosphate 23-26 purinergic receptor P2Y12 Homo sapiens 198-203 11502873-5 2001 HORK3, when transfected in the rat glioma cell subline (C6-15), responded to 2-methylthio-ADP (2MeSADP) (EC(50) = 0.08 nM) and ADP (EC(50) = 42 nM) with inhibition of forskolin-stimulated cAMP accumulation. Adenosine Diphosphate 90-93 purinergic receptor P2Y12 Homo sapiens 0-5 11502873-7 2001 These results show that HORK3 is a Gi/o-coupled receptor and that its natural ligand is ADP. Adenosine Diphosphate 88-91 purinergic receptor P2Y12 Homo sapiens 24-29 11413167-5 2001 Recently, we cloned a human orphan receptor, SP1999, highly expressed in brain and platelets, which responded to ADP and had a pharmacological profile similar to that of P2Y12. Adenosine Diphosphate 113-116 purinergic receptor P2Y12 Homo sapiens 45-51 11104774-0 2001 ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 68-74 11104774-10 2001 ADP was subsequently shown to inhibit forskolin-stimulated adenylyl cyclase activity through selective activation of SP1999 with an EC(50) of 60 nM. Adenosine Diphosphate 0-3 purinergic receptor P2Y12 Homo sapiens 117-123 11104774-11 2001 Other nucleotides were able to activate SP1999 with a rank order of potency 2-MeS-ATP = 2-MeS-ADP > ADP = adenosine 5"-O-2-(thio)diphosphate > 2-Cl-ATP > adenosine 5"-O-(thiotriphosphate). Adenosine Diphosphate 94-97 purinergic receptor P2Y12 Homo sapiens 40-46